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Abstract
Genetic Pathway Analysis of Abnormal Facial Development in
Nonsyndromic Cleft Lip and Palate

Lorena Maili, M.S.

Advisory Professor: Jacqueline Hecht, Ph.D.

Nonsyndromic cleft lip with or without cleft palate (NSCLP) is the most common
craniofacial birth defect resulting from incomplete fusion of the facial prominences during
development, which leaves a gap in the lip, primary palate and/or the secondary palate.
NSCLP affects 135,000 NSCLP newborns worldwide each year based on a birth
prevalence of 1 per 700 live births. While surgical treatments have dramatically improved,
many long-term health issues persist, imposing significant medical, psychosocial and
economic burdens.

Familial aggregation and segregation analyses suggest genetic

contributions underlie NSCLP, but despite decades of study, only a small portion of the
NSCLP genetic liability has been identified leaving a large knowledge gap. Following a
pathway-based approach to identify NSCLP etiologic genes, this dissertation examined
gene networks regulating facial morphogenesis. Three different pathways were assessed
and found to have etiologic roles in NSCLP. The PBX pathway, implicated in murine
midfacial development, was confirmed to be associated with NSCLP in our family-based
and case-control datasets. The second gene, identified in the CRISPLD2 network, was
found to play a novel role in regulating oral and facial development, with perturbation
causing abnormal oral morphogenesis in zebrafish. The final study used bioinformatic,
cell-based and transgenic zebrafish approaches together to identify noncoding variants in
FZD6, LRP5, LRP6 and DKK1 driving allele-specific expression during craniofacial
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development. Testing of these variants in our extensive family-based NSCLP dataset
identified, for the first time, associations between LRP5 and DKK1 and NSCLP, and
confirmed the previously identified association with FZD6 and LRP6. These results
support the analysis of gene networks rather than individual genes to identify the missing
heritability underlying NSCLP.

This approach is critical towards understanding the

polygenic contributions that are known to underlie NSCLP and other complex disorders.
The goal of these studies is to construct and map all of the noncoding and coding variants
contributing to NSCLP, with the ultimate goal of determining individual and family risks,
so that the information can be used in the clinic setting.
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1.1 Introduction
Nonsyndromic cleft lip with or without cleft palate (NSCLP) is the most common craniofacial
birth defect, with a birth prevalence of 1 in 700 live births and affecting approximately 4000
newborns in the United States and 130,000 babies worldwide each year [1-3] (CDC 2006).
Despite decades of research, the causative factors are largely unknown. The studies in this
dissertation aim to increase our understanding of the underlying genetic causes of abnormal
facial development in NSCLP in order to create better diagnostics for at-risk individuals and
advance therapeutic interventions. The clinical features of NSCLP, facial development and
molecular mechanisms that influence it as well as known genetic contributions are reviewed
to set the stage for what was learned from this work.

1.2 Clinical Features of Orofacial Clefts
Orofacial clefts are structural malformations that arise from incomplete fusion of the facial
prominences during development, leaving a gap in the lip, palate or a combination of both [4]
(Figure 1). Clefts occur unilaterally in 80% of cases, more often affecting the left side of face
and bilaterally in the remaining 20%; males are affected twice as frequently as females [5, 6].
The birth prevalence varies depending on geographic regions and ethnic populations with
East Asian and Native Americans having the highest birth prevalence and African ancestry
populations having the lowest [2, 7].

Figure 1: Clinical manifestations of orofacial clefts.
14

The mildest manifestation is a unilateral microform cleft lip, where a notch is present in the
upper lip (vermillion) and a scar-like band of fibrous tissue occurs from the lip to the nostril
(also minor nasal deformities can be present) [8, 9]. The fibrous tissue is thought to be a scar
from delayed lip closure (as a mild form of the defect) or from spontaneous repair of the cleft
in utero by unknown mechanisms [9]. The most severe form is bilateral complete cleft lip and
palate, which requires the most extensive surgical and rehabilitative therapy [10].
In addition to the cleft anomaly, other structural abnormalities include a short philtrum,
abnormal orbicularis oris muscle (muscle in the upper lip is inserted in parts of the nose),
structural deformities that affect the appearance and function of the nose, disruptions in the
alveolar bone and dental anomalies [11, 12].
Developmentally, orofacial clefts can be divided into cleft palate only or cleft lip with or without
cleft palate. Additionally, in syndromic forms, clefts can be one of multiple clinical features.
To date, over 400 syndromes include an orofacial cleft as a clinical feature, including van der
Woude, Stickler and Treacher Collins syndromes [4, 7]. The majority of clefts, however,
manifest without any other structural, functional or behavioral abnormalities and are the focus
of this work.

1.3 Nonsyndromic Cleft Lip and Palate
Nonsyndromic cleft lip with or without cleft palate (NSCLP) is postulated to follow the
multifactorial model of inheritance, which involves both genetic and environmental interacting
factors that each have a small effect, but act together in an additive manner [6, 13-15] [16].
The genetic component is estimated to be high in NSLCP, with some heritability estimates of
greater than 70% [17].
Family studies, the first of which were documented by Fogh Anderson in 1942, have shown a
strong familial aggregation; individuals with an affected first degree relative have a 32 times
15

higher relative risk compared to the general population [18, 19]. This relative risk decreases
with familial distance. Additionally, the concordance rate is higher in monozygotic twins (4060%) compared to dizygotic twins (3-5%) strongly implicating genetic factors. Based on these
findings, both candidate gene and genome-wide interrogations have been applied in the last
several decades with some success in identifying genetic contributions to NSCLP [4, 20, 21].

1.3 Genetic studies of NSCLP
Approximately 30-40 genetic loci influencing risk to orofacial clefts have been identified
through linkage and genome wide association studies (GWAS). Twelve GWAS loci have
been replicated in other studies and meta-analyses [4, 22]. Candidate genes in/close to
linkage and GWAS regions include ARHGAP29, CRISPLD2, FOXE1, IRF6, MSX1 TGFA,
RARA, andTP63 among others [4, 22, 23]. Surprisingly, IRF6 is the only gene supported by
both linkage and GWAS methods [24]. This could be due to high genetic heterogeneity
contributing to NSCLP. Additionally, the identified genetic variation so far includes common
single nucleotide variants (SNVs), low frequency variants, copy number variants and
deNovo/rare mutations, the latter of which are usually restricted (private) to specific families
[25-30].

1.4 Gene Pathways implicated NSCLP
Results from both human genetic studies and animal models support the dysregulation of
genes and signaling pathways contributing to NSCLP, including WNT, FGF, BMP, and TGFB among others [31, 32]. This is consistent with the multifactorial model, where multiple genes
interact with each other or environmental factors to contribute to NSCLP. Pathway analyses
or methods that detect gene-gene interactions have the potential to discover or amplify signals
from combinatorial contributions from multiple genes [24]. We have successfully used this
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approach to confirm previously nominated genes and to identify new candidate NSCLP gene
networks [33, 34].

1.5 Noncoding variants in NSCLP
Interestingly, several loci identified in linkage studies are not near any genes and the majority
of GWAS SNVs meeting genome-wide association thresholds are noncoding variants, found
either upstream, downstream or in introns of genes [35]. Although they don’t code for proteins
or alter protein sequence, noncoding variants can harbor regulatory elements such as
enhancers, silencers, promoters and noncoding RNAs which have the potential to modify
transcription and alter the dosage of gene expression [36, 37]. It has been shown that
enhancer elements alter facial morphology by fine-tuning gene expression during embryonic
development to create circumstances that allow for nonsyndromic clefts to occur [38]. We
and others have recently found support for craniofacial enhancer elements contributing to
NSCLP [39, 40]. Further identification and interrogation of such variants, as well as their
functional consequences, is an exciting direction for current/future research in the genetics of
NSCLP.

1.8 Craniofacial embryology
Orofacial development is complex, involving multiple biological processes and growth factors
with precise timing of tissue movement and fusion [41, 42]. The information pertaining to
upper lip and palate development is derived from studies of human fetuses but also detailed
experiments in animal models [43].

17

Figure 1: Embryonic facial development.

Facial development starts during the fourth gestational week, when the neural crest cells
(NCCs), a transient population of multipotent cells, delaminate from the cephalic neural tube,
migrate and combine with the core mesoderm and epithelial cover and proliferate to give rise
to the 5 facial primordia [4, 5] (Figure 2). These primordia are the frontonasal prominence
(FNP), the paired mandibular processes and the paired maxillary processes. At week 5, the
nasal placodes appear and divide the medial (MNP) and lateral nasal processes (LNP) [4].
During weeks 6 and 7, the maxillary processes grow medially and fuse with the nasal
processes to give rise to a complete upper lip and primary palate [4]. The secondary palate is
formed when the palatal shelves grow out from the MXP during the sixth week and elevate
above the tongue to subsequently fuse during weeks 9 - 12 to form the roof of the oral cavity
[4]. Importantly, because the fusion of the lip and primary palate takes place first, the
presence of a cleft in the lip can affect the fusion of structures in the palate, which is why cleft
lip and palate often occur together [4].
Interestingly, as the facial primordia are growing and fusing, the brain is also developing and
in turn, influencing the face through both physical and molecular interactions [44-46]. The
brain acts as a platform and influences the shape, growth and displacement of the facial
primordia [44]. One theory is that if the brain is growing very quickly, then the prominences
have a smaller window to make contact and fuse and this scenario might increase the

18

likelihood of a cleft to occur [44, 45]. In the case of NSCLP, this is plausible as there are no
other malformations, and minor/subtle changes in the brains of patients with NSCLP have
been reported [47, 48].

1.9 WNT signaling in facial development
While many signaling pathways are known regulate craniofacial development, among them
BMP, FGF, SHH and others, Wnt signaling, the focus of this dissertation, as it is one of the
key pathways affecting many stages, from migration of NCCs to the growth and fusion of the
facial prominences [49]. Wnt signaling transductions can be divided into canonical (β-catenin
mediated) and non-canonical pathways and both are important during facial development [49,
50]. There are 19 secreted WNTs transcribed from closely related genes that are similar in
size, which bind to 10 frizzled receptors coupled to 2 LDL co-receptors (LRP5 and LRP6) [51].
The interaction between the ligands and receptors is mediated by conserved residues and
although several WNT ligands preferentially bind to certain FZD receptors this is driven mostly
by cellular context and adds to the complexity of how and when this pathway functions [51].

Figure 2: The WNT signaling pathway.
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The β-catenin mediated Wnt pathway is activated when a Wnt ligand binds a frizzled (Fzd)
receptor and a low-density lipoprotein-related protein 5 or 6 (LRP5/6) co-receptor, leading to
inhibition of the β-catenin destruction complex [49, 50]. This allows for the accumulation of βcatenin in the cytoplasm [49, 50]. β-catenin can then translocate into the nucleus and interact
with lymphoid enhancer-binding factor or T cell-specific transcription factor (TCF/LEF) in
WNT-responsive DNA elements and regulate the transcription of specific genes [49, 50]. The
inhibitors for this pathway, Dickopff (DKK) family members, bind to LRP5/6 and antagonize
Wnt ligands to downregulate β-catenin signaling [49].
Canonical (β-catenin) Wnt signaling is active in both the ectoderm and underlying
mesenchyme of the facial prominences and palatal shelves [49]. This signaling marks areas
of high growth and, in mammals, it is more intensely expressed in lateral regions such as the
maxilla, and low or absent in the midline regions or the frontonasal prominence [52]. Wnt
mutant mouse models highlight the importance of dosage (fine tuning) in signaling by
revealing that both too little and too much canonical Wnt signaling can lead to craniofacial
deformity phenotypes that include cleft lip and palate [49]. There is an inbred strain (A-) of
mice that exhibits multifactorial nonsyndromic clefting (A/WySn and compound Wnt9b-/clf1
mutants) [53]. These mice have mutations that affect Wnt signaling through cis interference
and epigenetic control of Wnt9b transcription [53-58]. They exhibit abnormalities in size and
shape of the facial prominences during development and the frequency of clefts can be
anywhere from 10%-90% [53].

A study investigating signaling at the mouse lamboidal

junction, where the MXP, MNP and LNP make contact, found that the Pbx transcription factors
dysregulated Wnt signaling and decreased apoptosis at the fusion site, triggering completely
penetrant bilateral clefts [59]. Additionally, there is a long-range murine enhancer harbored
by the 8q24 region that acts on Myc expression and causes dysregulation of Wnt pathway
genes (Fzd6, Wnt5A, Wnt9b, TCF4, Dkk1 and Lef1) [60]. Deletions in this enhancer lead to
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cleft lip in 7% of mutant mice and alter facial features such as the snout, frontal bones, width
of MPN and others in the rest [60].
In summary, Wnt β-catenin pathway genes are important for normal development of the upper
lip and palate, and disturbances in this pathway lead to altered facial morphology, including
orofacial clefts.

1.10 WNT pathway genes
WNT signaling genes have been identified as causative factors in both syndromic and
nonsyndromic forms of CLP [31]. For example, while mutations in WNT3 and WNT5A are
associated with syndromic clefts in tetra-amelia and Robinow syndrome, noncoding variants
in WNT3, WNT3A, WNT5A, WNT9B and WNT11 have been associated with NSCLP in
European, European American, Latin American, Hispanic and Chinese populations [31, 6164]. All components of the pathway, including 9 ligand genes, 4 receptor and co-receptor
genes, 3 β-catenin partners and LEF1 have been implicated, through various studies of
orofacial clefts, in the last 20 years [31].
A GWAS study identified a variant in FZD6 that segregated through all 11 individuals with
NSCLP in a large African American family [65]. This variant, rs138557689, is located in intron
1, approximately 700 bp upstream of the start site in exon 2 [65]. Experiments to understand
the functional consequences of the C allele found that it created an additional protein binding
site that led to ~80% reduction in promoter activity [65]. Fzd6 is expressed in the mandible
and maxilla during murine development [66-68].

It negatively regulates canonical WNT

signaling and down-regulates TCF/LEF binding and subsequent transcription of WNT target
genes [69]. Both knockdown and overexpression of fzd6 in zebrafish cause craniofacial
anomalies such as a reduced ethmoid plate and abnormal mandibular cartilages [65]. Taken
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together these findings suggest that noncoding variants can modulate FZD6 expression and
dysregulate WNT signaling during development to contribute to nonsyndromic cleft formation.
Frizzled receptors require LRP5/6 as co-receptors, with LRP6 being a key co-receptor for the
β-catenin pathway [51, 70]. Mutations in LRP5 are associated with craniosynostosis, torus
palatinus and a thick mandibular ramus in humans while frameshift and missense mutations
in LRP6 are associated with orofacial clefts and tooth agenesis [71-74]. Zebrafish knockdown
and mutant models of lrp5 exhibit abnormal craniofacial cartilages while lrp6 null mice have
fully penetrant bilateral clefts and mandible defects [73, 75]. Dkk1 is the major inhibitor of
canonical Wnt signaling [76]. In Xenopus, it induces head formation, while Dkk1 null mice
display severe craniofacial abnormalities and completely lack facial structures [76, 77].
Overexpression of Dkk1 in Wnt reporter mice showed an altered Wnt activation pattern in the
developing craniofacies and changed the morphology of the facial prominences [52]. In
humans, missense mutations in DKK1 are found in patients with holoprosencephaly, a
developmental disorder that affects the brain and face where a small percentage (~8%) of
patients present with a median cleft [78, 79]. Taken together, this information nominates these
4 genes at the crux of Wnt signaling, which interact together at the receptor level, as strong
NSLP candidate genes.

1.11 Significance
Although many susceptibility loci, genes and variants have been identified in NSLCP, our
complete understanding of the genetic contributors is still lacking [40, 80]. As research efforts
continue, gene pathway analysis and noncoding variants with regulatory effects on gene
expression are becoming the focus of many research studies. Noncoding variants typically
have effects in specific tissues at specific developmental timepoints, a concept of particular
interest to understanding how nonsyndromic clefts might occur. Both the contribution of
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multiple genes and the resulting alterations from noncoding variation fit the multifactorial
model proposed more than five decades ago, where multiple factors with small effects push
the phenotype to the threshold past which the disorder occurs. Precise control of gene
expression is crucial, especially during development, when any perturbation in might lead to
abnormalities.
The goal of this dissertation was to investigate gene pathways with supporting roles in
craniofacial development, characterize such genes for their contributions to facial
development, and to examine noncoding variation in a pathway of genes that work together
at the receptor level of Wnt singaling, an important modulator of orofacial morphogenesis.
The results are presented in the following chapters. Chapter 3 describes the confirmation of
a PBX-driven pathway identified in mice for contributions to human NSCLP. Chapter 4
describes the characterization of a CRISPLD2-network gene, FOS, in vertebrate craniofacial
development and morphogenesis. Chapter 5 combines approaches in Chapters 3 and 4 to
examine functional noncoding variants for allele-specific expression in early craniofacial
development and tests these variants for association in NSCLP families. Altogether, these
studies demonstrate the usefulness of examining gene pathways and noncoding variants to
understand the genetic etiology of complex disorders such as NSCLP and further the field in
beginning to close the knowledge gap on NSCLPs heritability.
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CHAPTER 2: MATERIALS AND METHODS
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2.1 Prioritization of noncoding variants
DbSNP database was used to retrieve all variants upstream of the coding region of each gene
[81]. Linkage disequilibrium for the upstream region of each gene was plotted using HapMap
data in Haploview [82]. Global minor allele frequency was used to exclude rare variants so
that the prioritized list would be informative for genotyping studies.
Genomic Evolutionary Rate Profiling (GERP) score was to estimate the evolutionary
constraint rates for individual nucleotide positions [83, 84].

The base-wise genomic

evolutionary rate profiling (GERP) was obtained from UCSC genome browser for each variant.
GERP scores, which range from -12 to +6, indicate evolutionary constraint when positive;
variants with positive scores were prioritized for use in this study [83, 84].
Ensembl Variant Effect Predictor (VEP) was used to identify the effect of each variant on the
gene transcript. Genome Wide Annotation of Variants (GWAVA) was used to annotate
variants in noncoding regions for potential functionality; this tool calculates a score for each
SNV, with scores higher than 0.5 indicating functionality [85]. HaploReg V4.1, which employs
Roadmap Epigenomics and ENCODE data, sequence conservation across mammals
(SiPhy), and eQTL data, was used to further assess functionality annotations [86, 87].
HaploReg also annotates promoter histone marks, enhancer histone marks, DNAse
hypersensitivity, proteins bound by ChIP-seq experiments, binding motifs, and expression
quantitative trait loci (eQTLs) on various cell lines and tissues [86, 87]. The Genotype-Tissue
Expression (GTEx) portal was utilized to predict the effect of SNVs in different human tissues
[88, 89].
Lastly in silico analysis of transcription factor binding sites was performed using Alibaba, Patch
and Promo [90, 91]. Variants that were common, were evolutionarily conserved, designated
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functional by predictor tools, and altered transcription factor binding sites in at least 2 in silico
analyses were prioritized.

2.2 Electrophoretic mobility shift assay (EMSA)
Oligonucleotides were synthesized end-labeled with an infrared dye by Integrated DNA
Technologies (Coralville, IA).

They were annealed using standard protocols.

Human

embryonic kidney (HEK293) cell nuclear extracts were purchased from ActiveMotif (Carlsbad,
CA). Electrophoretic mobility shift assays (EMSAs) were performed by incubating 2.5 lg
nuclear extract, labeled probe and 1 lL of dG/dC in a 20 lL mixture containing 20 mmol/L Tris
pH 7.5, 50 mmol/L KCl, 10% glycerol, 0.5 mmol/L EDTA (ethylenediaminetetracetic acid), 0.5
mmol/L DTT (dithiothreitol), 0.05% NP-40 (nonyl phenoxypolyethoxylethanol) and 1 mmol/L
PMSF (phenylmethanesulfonylfluoride) for 1 h at 4°C. 10X Orange loading dye was added to
monitor electrophoresis (Li-Cor, Liconln, NE). Competition assays included 5-, 10-, and 50fold excess of cold probe. Negative controls were prepared using the labeled probes and
binding buffer without the nuclear extract.

All samples were loaded on a prerun 5%

polyacrylamide gel in 1X TBE. After electrophoresis for 3 h at 150 V, the gel was imaged
using the Odyssey infrared scanner (Li-Cor, Lincoln, NE).

2.3 Luciferase assays
Luciferase reporter constructs were obtained from Switchgear Genomics (Carlsbad, CA) and
20-basepair sequences containing each variant was cloned upstream of its respective gene
promoter by InFusion cloning (Takara Bio USA, Mountain View, CA). The alternate allele
construct was created using the Quick Change II site-directed mutagenesis kit (Agilent, Santa
Clara, CA). 293T, HeLa and MCF7 cells (ATCC, Manassas, VA) were seeded at 100,000 cells
per well in a 96-well plate, and allowed to grow for 24 hours in complete media before being
transfected with control and experimental constructs. Additionally, an internal control to
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ensure the efficiency of transfection, was used by co-transfecting Cypridina TK.

Each

condition was transfected triplicate and each experiment was performed at least three times.
The LightSwitch Luciferase Assay Kit (Switchgear Genomics, Carlsbad, CA) was used
following the manufacturers protocol to measure both Renilla luciferase and Cypridina TK
luciferase in the Tecan plate reader (Männedorf, Switzerland). For analysis, each well was
normalized to the internal control and p < 0.05 was considered significant).

2.4 Zebrafish care and husbandry
Zebrafish (D. rerio) were housed and maintained at 28°C as previously described
(Westerfield, 2000). All work involving the use of animals was performed with approval of the
UTHealth Animal Welfare Committee (AWC-20-0052). Wild type controls were from the AB
mapping reference strain. Tg(-4.9sox10:GFP) were obtained from ZIRC and Tg(7xTCFXla.Siam:GFP) transgenic lines were obtained from Moro et al [92].

2.5 Morpholino and CRISPR/Cas9 injections
Zebrafish antisense morpholinos (fzd6 MO: TTAACCGCAAACCTCCTCCTCTTCC lrp5 MO:
CGGGCTTTAATTCCATAATCCCAGC, lrp6 MO: AGAGAGTCTGAAGCACGGCACCCAT,
and dkk1 MO: AATTGTAGGATGTATTCCCTGGGTG) targeting the ATG start sites and
mismatched control morpholinos were designed by GeneTools. Morpholinos were suspended
in MilliQ water to a stock concentration of 16.67mg/mL or 2mM. Injections of morpholinos
were diluted to 0.5 ng/uL to 3ng/nL in Danieu buffer.
mRNA was generated using the mMessage mMachine Sp6 kit (Ambion). mRNA was
resuspended in nuclease-free water to a stock concentration of 2ng/nL and diluted to 0.5ng/nL
in 0.1M KCl for injections.
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Fzd6 F0 mutants were created using IDT Alt-R™ CRISPR-Cas9 System (Coralville, IA).
Three CRISPR RNAs (crRNAs) specific to fzd6 gene, one pair targeting exon 2 and the other
exon 4 (A: GCTGTAGACGTGACCACGGC, B: CACGGGCCTGTACGACCTGA and C:
CATGCTGGAGCACTACGACC) were hybridized separately with trans activating crispr RNA
(tracrRNA) to form a functional gRNA complex. 60uM of each gRNA was incubated with 5ug/ul
of Cas9 protein (Alt-R® S.p. Cas9 Nuclease, IDT) for 10 minutes at 37°C to generate the
ribonucleoprotein (RNP) complex. Equimolar amounts of the two RNPs were mixed and
injected into the zebrafish embryos.

Mutagenesis was detected by PCR using primers

TCTACACACATTAAACACACAGCA and CAGAGCGGCTCCTTCCT. Sanger sequencing
was used to specify the mutations created and the Synthego ICE tool was used to estimate
editing efficiency for each guide (Synthego, Redwood City, CA). For all zebrafish injections,
one-cell embryos were injected with 1nL of MO, MM or RNPs.

2.6 Zebrafish Facial Analytics based on Coordinate Extrapolate system
(zFACE)
Zebrafish embryos were fixed in 4% paraformaldehyde (PFA) (Millipore Sigma, Burlington,
MA) in 1X phosphate buffered saline with Triton X-100 (PBST) at room temperature for 4
hours and stained with 0.2mg/L DAPI (Thermo Fisher, Waltham, MA) for 30 minutes at room
temperature. Embryos were mounted rostrally in 1% low-melt agarose (Research Products
International, Mount Prospect, IL) and imaged with Zeiss LSM800 Confocal Microscope
(Dublin, CA). Twenty-six anatomic landmarks including eyes, olfactory pits, neuromasts and
mouth were identified from the confocal images and measurements between these landmarks
were calculated to extract phenotypic features and understand which anatomical structures
were altered as a result of fos knockdown. ANOVA and Tukey test for multiple comparisons
were applied or each measurement and Bonferroni correction for 39 measurements was
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applied to determine statistical significance. GraphPad Prism 9.0.0 was used to plot and
visualize the data.
After this feature-focused analysis, dimensionality reduction was performed using Principal
Component Analysis (PCA) in StataIC 14 (StataCorp. 2015). Components with an eigenvalue
of greater than or equal to 1 (following the Kaiser-Guttman method) were retained for analysis.
Promax rotation, which accounts for correlations between the different factors (zFace
measurements) was used because a high correlation was observed/ expected between
features calculated using shared landmarks. Principal component (PC) scores were predicted
and logistic regression models were utilized to regress morphant/mutant status by PC scores.
Additionally, to focus on facial shape and remove variation due to size, position, or rotation,
the 2D landmark data points from the 26 zFACE coordinates were uploaded into MorphoJ
version 1.07A and principal axes Procrustes superimposition was performed [93]. After
Procrustes transformation, PCA was used to examine general shape variation in the
combined groups while discriminant function analysis (DFA) with 10,000 permutations for the
mean Procrustes distance was used to assess significant differences between the groups.

2.7 Skeletal staining
Alcian blue (Anatech LTD) and alizarin red (Sigma‐Aldrich) staining was performed to
visualize the bone and cartilage structures using standard techniques [94]. Briefly, 5-8 dpf
embryos were collected and fixed in 2% PFA/1X PBXT for 1 h at room temperature and stored
in methanol over night at −20°C. After removing methanol, embryos were incubated in 0.04%
alcian blue solution (100 mmol/L Tris, pH 7.5, 10 mmol/L MgCl2, 64% ethanol) overnight at
room temperature.

They were de-stained in 3% H2O2/0.5% KOH for 10 min at room

temperature and then stained in 0.02% alizarin red solution (100 mmol/L Tris, pH 7.5, 25%
glycerol) for 30 min at room temperature. Embryos were then de-stained in 50% glycerol/0.1%
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KOH for 30 min and stored in 50% glycerol. Imaging was performed using the LAS Montage
Module (Leica).

2.8 Generation of transgenic reporter lines
Variant specific sequences containing each variant allele flanked by 25-50 bp and attB4 and
attB1r recombination sequences were ordered from IDT Technologies (Coralville, IA). These
variant sequences were recombined into pDONRP4-P1R using BP clonase (ThermoFisher,
Waltham, MA). QuickChange II kit was used to create the alternate allele for each construct
(Agilent, Santa Clara, CA). Each of these constructs were then recombined with donor
constructs that contained a gata2 promoter and either a eGFP or mCherry-polyA cassette
(Bhatia et al 2014) into either pDestTol2CG2 or pMinTol2R4R2, destination vectors with Tol2
recombination sites. These resulting expression plasmids were then isolated, purified and
diluted to 50 ng/uL and mixed with the same concentration of Tol2 transposase before
injections. Injections of 1-2 nL were injected into fertilized embryos at the 1 cell stage.
Embryos that were screened for reporter activity were raised for 3 months and in-crossed or
outcrossed with wild type animals to produce stable germline transgenic reporter fish.
To detect reporter activity, F0 and F1 embryos were fixed, DAPI stained and mounted in 1%
low melting agarose and imaged in the ZEISS LSM confocal microscope (Dublin, CA) from 1
to 5 days post fertilization (dpf). Fluorescence was quantified using ImageJ [95] and p < 0.05
was the threshold for statistical significance.

2.9 Drug treatments
The WNT activator drug BIO (Sigma, B1686) and WNT inhibitor IWR-1 (Sigma, I0161) were
dissolved in DMSO to 1 uM and 10 uM concentrations, respectively, and added to E3 media
of dechorinated embryos starting at 24 hours post fertilization for IWR-1 and 48 hours post
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fertilization for BIO. Treatment was repeated up to day 5 post fertilization by changing the E3
media and drugs once a day until collection. Untreated and DMSO treated dishes were also
used as controls to eliminate any toxicity due to the DMSO solvent. All dishes were incubated
in the dark. Embryos were fixed in 4% PFA with PBST for 4 hours at 4°C and DAPI stained
before being imaged in 1% agarose in the ZEISS LSM800 confocal microscope (Dublin, CA).

2.10 Family dataset
This study was approved by the University of Texas Health Science Center Committee for
Protection of Human Subjects (HSC-MS-03-090). The family-based dataset consisted of
2,233 individuals belonging to 780 NSCLP families, 243 multiplex families (145 nonHispanic
White (NHW); 87 Hispanic) and 564 simplex parent-child trios (335 NHW and 213 Hispanic).
Each family was ascertained through a NSCLP proband from one of four craniofacial centers:
Boston Children’s Hospital, Texas Children’s Hospital, Shriners Hospital for Children-Houston
and the McGovern Medical School UTHealth Craniofacial Center. Probands and relatives
were examined to exclude syndromic forms of orofacial clefting.
race/ethnicity was obtained by self-report.

Information about

After informed consent, blood and/or saliva

samples were collected and genomic DNA was extracted using established protocols.

2.11 Genotyping
The four single nucleotide variants (SNVs) upstream of FZD6, LRP5, LRP6 and DKK1 genes
were genotyped using Taqman genotyping assays and genotypes were detected on a ViiA7
Automatic Sequence Detection System (Life Technologies, Foster City, CA, USA). Control
individuals with known genotypes as well as non-template control samples were included on
all plates for the genotyping experiments.
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2.12 Statistical Analysis for Association Studies
Tests for Hardy Weinberg equilibrium were performed on all unaffected individuals in our
family dataset that did not have parent data (unaffected individuals and married-in individuals)
using Fisher’s exact tests. Family-based single SNV association analyses were performed
using the Family-Based Association Test (FBAT) [96]. The “- e” extension was applied to
correct for complex pedigree structures [97]. Association in the Presence of Linkage (APL)
was used in the individual and pairwise-association analyses [98, 99].

Analyses were

stratified by ethnicity and presence/absence of family history of NSCLP [98]. For all analyses,
the Bonferroni multiple testing corrected p-value (0.05/ number of SNVs) was considered
significant.
Transmission of all possible intragenic 2, 3 and 4-SNV haplotypes was examined using the
Haplotype Based Association Test (HBAT) function in FBAT [96, 100-102]. The significance
threshold was based on the number of possible gene-gene SNV combinations and was set at
p-value≤0.0125 (0.05/4 total SNVs).
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CHAPTER 3: PBX-WNT-P63-IRF6 pathway in nonsyndromic cleft lip and palate
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3.0 Introduction
NSCLP has multifactorial etiology in which numerous genes and environmental factors
individually or interactively may contribute to the phenotype [4, 103, 104]. Over the years,
numerous studies have successfully identified many genes/loci contributing to NSCLP [4, 32,
105]. Previous linkage, candidate gene and genome-wide association studies using familybased or case-control populations, and studies in animal models have provided evidence for
the role of MSX1, IRF6, TFAP2A, CRISPLD2, 8q24 locus, TP63, and WNT genes, among
other genes/loci in NSCLP [4, 105-107]. More recently, whole exome sequencing (WES)
studies have confirmed the role of variants in known NSCLP genes (IRF6, CDH1, CRISPLD2,
FGFR2 and PAX7) and identified novel candidate genes (CTNND1, PLEKHA7, PLEKHA5
and ESRP2) [25, 108, 109]. Furthermore, there is increasing evidence supporting an additive
role for gene-gene interactions in NSCLP, with modifier phenotypic effects [33, 110-114].

In this context, a novel genetic pathway comprised of Pbx-Wnt-p63-Irf6 genes was shown to
control murine facial morphogenesis and was proposed to be an important regulatory pathway
for NSCLP [59].

Pbx genes (Pbx1, -2, -3) and their respective encoded proteins are

considered Hox factors, which increase Hox DNA-binding specificity and are important players
during skeletal development [115-117].

Compound Pbx mutant mice presented with

craniofacial abnormalities and fully penetrant bilateral cleft lip and palate, which was attributed
to altered Wnt signaling at the midfacial region [59].

Expression of Wnt9b, Wnt3, and p63

was not detected in the midface of compound Pbx mutant mice in comparison to wild type
littermates; meanwhile Fgf8 and Irf6 expression was dramatically reduced [59]. This led to
the conclusion that loss of Pbx genes in the mouse midfacial region disrupts this Wnt-p63-Irf6
regulatory pathway, which in turn causes facial morphogenesis defects resulting in cleft
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lip/palate [59]. Based on these findings, we asked whether variation in genes in the proposed
PBX-WNT-P63-IRF6 pathway and their potential interactions might contribute to NSCLP.

3.1 Materials and methods
The methodology workflow is described in Figure 4.

Figure 3: PBX study methodology workflow.

35

3.1.1 Family discovery and case control validation datasets
The details of the NSCLP family, sample collection, SNV selection criteria, genotyping and
statistical analyses are described in Chapter 2. Briefly, for this study, 2,233 individuals
belonging to 780 families, 243 multiplex families (145 nonHispanic White (NHW); 87 Hispanic)
and 564 simplex parent-child trios (335 NHW and 213 Hispanic) were genotyped (Table 1).

A case-control NSCLP group, comprised of 945 unrelated individuals (504 individuals with
NSCLP and 441 controls without NSCLP or family history of NSCLP), was used to validate
the family-based results. Subjects were recruited under local IRB-approved protocols and
written informed consent at the Hospital of Rehabilitation and Craniofacial Anomalies, Bauru
Dental School, University of Sao Paulo, and at the Center for Treatment of Craniofacial
Anomalies, Rio de Janeiro, Brazil. Only Caucasian individuals (from the Southeastern region
of Brazil and of predominantly European ancestry) were included. Ethnicity was self-reported
for up to 2 generations.
Table 1. Description of family-based and case-control NSCLP datasets
NSCLP Datasets
Case-Control2

Family-Based
Ethnicity
Families

Individuals

Individuals

Unaffecte
Simplex

Multiplex

Total

Affected

Total

Cases

Controls

Total

d

NHW1

335

145

480

934

553

1487

504

441

945

Hispanic

213

87

300

531

315

846

--

--

--

Total

548

232

780

1465

868

2333

504

441

945

1NHW

= nonHispanic white
individuals of European Caucasian ancestry

2Unrelated
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3.1.2 SNVs genotyped
Fourteen single nucleotide variants (SNVs) in/nearby PBX1, PBX2, and TP63 genes were
selected based on heterozygosity (minor allele frequency > 0.15%), location in gene, and
linkage disequilibrium blocks surrounding each gene as previously described and elaborated
in Chapter 2 [62]. These SNVs are described in Table 2.

3.1.3 Single SNV and haplotype association testing
Single SNV association analysis was performed using the Family-Based Association Test
(FBAT) with and without the “-e” extension to correct for complex pedigree structures [96].
Transmission of all possible intragenic 2, 3 and 4-SNV haplotypes was examined using the
Haplotype Based Association Test (HBAT) function in FBAT [96, 100, 102]. Association in
the Presence of Linkage (APL) was used for the individual and pairwise-association analyses
and stratified by ethnicity and presence/absence of family history of NSCLP [99].

The

Bonferroni method for multiple testing was used and a corrected p-value ≤0.0036 (0.05/14
SNVs) was considered significant.

Chi square and Fisher’s exact tests, as implemented in PLINK v.1.07 [118] were used to
detect differences in genotype and allele frequencies for each SNV between cases and
controls, with p-values ≤ 0.05 considered significant.

3.1.4 Gene-gene interaction analysis
APL was used to detect gene-gene interactions between the studied SNVs with 14 variants
in additional known NSCLP genes (WNT3, WNT9B and IRF6) for which genotype data was
available (Table 3) [62, 119]. The significance threshold was based on the number of possible
gene-gene SNV combinations and was set at p-value≤0.0019 (0.05/27 total SNVs).
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Table 2. SNV alleles and frequencies by ethnicity
Base
Gene

Chr

dbSNP ID
positiona

PBX1

PBX2

TP63

1q23

6p21.3

SNV

NHW

Hispanic

Controls

Locationc

MAFd

MAFe

MAF

Allelesb

164523953

rs6426870

CT

5’ (– 867)

0.27

0.47

0.34

164607346

rs1618566

AG

Intron 2

0.38

0.26

0.34

164658057

rs10800043

CT

Intron 2

0.21

0.27

0.25

164723835

rs7543038

GT

Intron 2

0.39

0.272

0.34

164782006

rs3767367

AG

Intron 6

0.18

0.14

0.17

32158319

rs176095

AG

5’ (-340)

0.20

0.15

0.20

32155581

rs204993

AG

Intron 4

0.26

0.18

0.22

32151934

rs3131300

AG

3’ (+576)

0.17

0.11

0.12

189341790

rs9332461

AG

5’ (-7388)

0.38

0.26

0.33

189421319

rs4575879

AG

Intron 1

0.37

0.31

0.37

189451290

rs4607088

CT

Intron 1

0.39

0.49

0.43

189497616

rs4686529

AG

Intron 3

0.46

0.38

0.50

189596855

rs1515490

AG

Intron 10

0.24

0.22

0.24

189641053

rs11706540

TC

3’ (+25988)

0.29

0.22

0.29

3q28

Chr= chromosomal location
a Ensembl

GRCh37 reference assembly position
common allele listed first.
c Distance from transcription start site in base pairs for upstream and downstream SNVs
d Minor allele frequency
e Corresponding frequency in Hispanic of nonHispanic White minor allele
b Most
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Table 3. WNT3, WNT9B and IRF6 SNVs used in gene-gene interaction calculations

Gene

WNT3

WNT9B

IRF6

Chr.

Base
positiona

dbSNP ID

Allelesb

NHW MAF
Frequencyc

Hispanic
Frequencyd

44795234

rs142167

A/G

0.26

0.52

44815743

rs7216231

A/G

0.06

0.41

44847834

rs199525

G/T

0.22

0.16

44859715

rs70602

C/T

0.22

0.15

44865603

rs199498

C/T

0.24

0.49

44871987

rs111769

C/T

0.42

0.26

44891301

rs3851781

C/T

0.47

0.66

44901449

rs9890413

A/G

0.36

0.22

44941366

rs2165846

A/G

0.42

0.72

44951777

rs1530364

A/G

0.26

0.32

44990522

rs197915

A/G

0.43

0.43

44928053#

rs12602434

C/G

0.14

0.34

209989270

rs642961

A/G

0.25

0.22

209964080

rs2235371

C/T

0.07

0.22

17q21

17q21

1q32.2

*Genotyped in Chiquet et al. 2008 (31) and Blanton et al. 2010 (38)
# Genotyped in this study
a Ensembl GRCh37 reference assembly position
b Most common allele listed first.
c Minor allele frequency
d Corresponding frequency in Hispanics of NHW minor allele
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3.2 Results
3.2.1 Single SNV associations
All SNVs were in Hardy-Weinberg equilibrium. In the family-based analysis, SNVs in all three
genes interrogated met the nominal association threshold of p ≤ 0.05 (Table 4).

After

Bonferroni correction, the most significant individual SNV associations were between PBX2
rs3131300 (p=0.003) with NSCLP in Hispanic families (Table 4). In the case-control group,
significant associations were found for PBX1 rs6426870 (p=0.007) and TP63 rs9332461
(p=0.03); no association was found for PBX2 (Table 4).

3.2.2 Haplotype associations
Analyses of 2-, 3-, and 4-window haplotypes revealed altered transmission of PBX2 alleles
involving rs3131300 in both Hispanic and NHW families. Interestingly, the alternate allele G
in rs3131300 was consistently over transmitted together with the ancestral alleles of rs176095
(A) and rs204993 (A) in NHW, whereas in Hispanic families over transmission of both alternate
alleles in rs3131300 and rs204993 (G-G) was detected (p<0.003; Table 5). Additional TP63
variant haplotypes were also significantly associated with NSCLP in Hispanics; in these
families the transmission of the alternate alleles in rs4607088 and rs4686529 (T-G) were
detected in combination with the ancestral alleles in rs9332461 (A), rs4575879 (A) and
rs1515490 (A) (p<0.003; Table 5).
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Table 4. Association results by ethnicity and pedigree type
Population
NHW#
Gene

SNV

Hispanic

All

Multiplex

FBAT
FBAT

FBAT
APL

FBAT

-e

rs6426870

Multiplex

FBAT
APL

FBAT

-e

FBAT
APL

FBAT

-e

Case Control

Simplex
FBAT
APL

FBAT

-e

APL

PLINK

-e

--

--

--

--

--

--

--

--

--

--

--

--

--

--

--

0.006

0.04

0.05

--

--

--

--

--

--

--

--

--

--

--

--

--

--

rs1618566

--

--

--

--

--

--

<0.05

--

--

--

--

--

--

--

--

--

rs204993

--

--

--

--

--

--

<0.05 <0.05

--

--

--

--

0.05

--

0.02

--

rs176095

--

--

--

--

--

--

--

--

--

--

--

--

--

--

rs3131300

--

--

--

0.02

0.02

0.04

0.03

--

--

--

0.01

0.014

0.02

--

rs9332461

--

--

--

--

--

--

--

--

--

0.005

0.01

--

--

--

--

0.03

rs4686529

--

--

0.02

--

--

--

--

--

--

--

--

--

--

--

--

--

PBX1 rs3767367

PBX2

All

NHW

--

--

0.003 0.003

TP63

p-values ≤ 0.05 are shown
p-values ≤ 0.0036 are significant after Bonferroni correction (in bold)
FBAT = Family Based Association Test, FBAT -e = option for extended pedigrees
APL = Association in the Presence of Linkage
# Results for NHW Simplex families are not shown because they were not significant
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Table 5. Haplotype results from NSCLP families
Gene

Alleles

P-value*

rs3131300 rs204993

G A

0.0002

rs3131300 rs176095

G A

0.0005

rs3131300 rs204993 rs176095

G A A

0.0006

rs3131300 rs204993

G A

0.0002

rs3131300 rs176095

G A

0.002

rs3131300 rs204993 rs176095

G A A

0.0003

rs3131300 rs204993

G G

0.003

rs9332461 rs4575879

A A

0.003

Hispanic

rs9332461 rs4607088 rs4686529

A T G

0.003

Multiplex

rs9332461 rs4607088 rs1515490

A T A

0.003

rs9332461 rs4607088 rs4686529 rs1515490

A T G A

0.003

Population

NHW All

PBX2
NHW Simplex

Hispanic All

SNVs

TP63



Minor alleles shown in bold
* APL test, significant if p-values ≤ 0.0036 (in bold)
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3.2.3 Gene-gene interactions
Gene-gene interaction analyses suggested numerous potential biological interactions, with
the majority observed in the NHW families. In the NHW families, considering multiplex and all
families, interactions were found between PBX1/PBX2/TP63 with IRF6, followed by PBX1 with
WNT9B (p0.0018). In Hispanics, evidence of interaction was also found between PBX1 and
WNT9B (p=0.0007). No significant interactions were observed between TP63 and either PBX
or WNT genes (Table 6).

Table 6. Summary of gene-gene interaction calculations in NSCLP families
NHW
Gene 1

SNV

Gene 2

All
rs10800043

WNT3

rs6426870

Hispanic

SNV
multiplex simplex

rs199525

All

multiplex simplex

0.0026
0.0007

rs1530364
WNT9B

rs3767367

PBX1

rs199498

0.0010

rs10800043

0.0017

0.0026

rs1618566

0.0018

0.0008

rs3767367

rs2235371

0.0003

IRF6
rs6426870

0.0004

0.0002

rs7543038

0.0013

0.0026

rs6426870
PBX2

rs176095

rs642961
WNT9B

rs1530364

0.0023
0.0003

0.0007

0.0001

0.0001

rs3131300

0.0007

0.0022

rs1515490

0.0009

rs176095
PBX2

0.0023

rs204993

IRF6

rs2235371

0.0001

0.0001

rs4607088

0.0031

0.0011

rs4686529

0.0004

rs4575879
TP63

IRF6

rs2235371

*interactions with p-values ≤ 0.0036 are shown; significant if p ≤ 0.0018 (in bold)
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3.2.4 Predicted functional consequences of associated SNVs
Bioinformatic predictions of the potential functional effects of associated SNVs on gene
expression are listed in Table 7. The downstream associated PBX2 variant rs3131300
showed evidence of evolutionary conservation, with a GERP score of 2.9. This variant was
classified as functional by GWAVA and as a modifier of the PBX2 gene transcript by Ensembl
VEP. The base pair change at this SNV affected 13 protein binding motifs, including BDP1,
KLF4, KLF7, PLAG1 and p300. Enhancer histone marks were present at the SNV location,
further implicating functionality.

PBX2 rs3131300 was also a significant expression

quantitative trait locus (eQTL) in whole blood samples, where individuals with an A allele show
higher PBX2 expression (Figure 5) [88].
The 5’ PBX1 rs6426870 variant had a neutral GERP score but was classified as functional by
GWAVA and harbored 6 altered binding motifs, including ones for FOXD1, FOXK1, FOXL1
and YY1. Additionally, this variant is also a significant eQTL in whole blood, and individuals
with a C allele show higher PBX1 expression (Figure 5).
The upstream TP63 variant rs9332461 was predicted to affect the protein-binding motif for
NKX2-1 and presented enhancer histone marks in blood and muscle tissues. This variant
was also a significant eQTL in lung tissue, with the A allele leading to higher TP63 expression
(Figure 5).
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Table 7. Bioinformatic analysis results
SNV

GERPa

Ensembl
VEPb

GWAVA
scorec

Enhancer
Histone
Marks

Proteins
bound

Motifs
Changed

eQTL

BDP1, CCNT2,
Klf4, Klf7, LXR,
brain,
PLAG1, PPAR,
POL2
muscle,
RREBPOL24H8
whole
1,UF1H3BETA,
blood
ZNF219,
Zfp281,
Zfp740, p300

2.9

Modifier,
downstream
gene
variant

0.87

fetal brain,
muscle

PBX1
rs6426870

-0.81

Modifier

0.69

-

-

Esr2, Foxd1,
Foxf2, Foxk1,
Foxl1, YY1

-

TP63
rs9332461

-6.81

Modifier

0.12

blood,
muscle

-

Nkx2.1

-

PBX2
rs3131300

a

GERP scores suggesting high conservation are bolded
ENSEBLE VEP designation is noted for effect on the gene of interest transcript
c GWAVA scores suggestive of functionality are bolded
d HaploReg functionality annotations
b

Figure 5. Violin plots from GTEx for the significant SNVs in this study.
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3.3 Discussion
In this study, we investigated the role of the PBX-WNT-TP63-IRF6 pathway in NSCLP
because this gene module resulted in clefting in Pbx-deficient mice [59]. The contribution of
IRF6, TP63 and individual WNT genes has been extensively studied in NSCLP and data
strongly supports them as cleft susceptibility genes in humans [4]. However, evidence
regarding the role of PBX genes in NSCLP, individually and/or interactively with additional
genes is still lacking. We tested whether variants in PBX and TP63 were associated with
NSCLP phenotypes in a large family-based group and in an independent case-control
validation group. We also performed gene-gene interaction calculations considering the
studied genes and additional known cleft genes. Overall, our results with two independent
datasets provide additional support for the contribution of the proposed PBX-WNT-TP63-IRF6
regulatory pathway to NSCLP risk. A significant association with PBX2 was found in our
NSCLP families and additional significant associations were found for PBX1 and TP63 in the
case-control group. Additionally, we observed evidence of altered allele transmission and
significant gene-gene interactions between PBX2-IRF6, PBX1-WNT9B-IRF6, and TP63IRF6, that further support the biological mechanisms previously proposed [59].
In the family-based analysis, PBX2 rs3131300 was significantly associated with NSCLP in
Hispanics and nominally associated in NHW families. Interestingly, PBX2 haplotypes
including this variant were significantly associated in both ethnic groups. In multiplex Hispanic
families, a marginal association was observed for TP63 rs9332461, and four haplotypes
containing this variant were significantly associated. Haplotype-based associations are
thought to be powerful approaches in addition to single variant analysis for complex diseases
because the inclusion of flanking variants has the potential to capture cis-interactions [120].
In the case-control analysis, the most significant associations were seen with PBX1
rs6426870 and TP63 rs9332461, whereas no association was found for PBX2.
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Figure 6. Gene pathway model linking human and mouse findings.
Family-based and case-control studies have different strengths in the types of associations
detected. Family studies have the advantage that family members share a common genetic
background and are also more likely to share environmental factors; whereas, case-control
studies can be well-powered when of adequate sample size and controlled for population
admixture effects [96, 121]. In this context, it is not unexpected to find that different variant
associations from the family-based and case-control groups. The aim of validation studies is
to obtain similar findings under modified influencing factors such as ethnic background,
phenotype, or sampling scheme. As a consequence, results from validation studies can be
different from those obtained with the discovery analysis because of both random and
systematic variation [122].
The associated variants in this study are all located in noncoding regions, downstream
(rs3131300) and upstream (rs6426870 and rs9332461) of their respective genes, and
therefore of potential functional significance. Although determining the biological effects of
these variants will require functional studies, their location and predicted functions suggest
biological relevance to craniofacial development and/or NSCLP. PBX2 rs3131300 is located
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in a conserved region associated with enhancer histone marks in skin, muscle and nerve
tissues, and predicted to alter 13 transcription factor binding motifs, including Klf4 and p300.
Interestingly, missense variants in Klf4, an important regulator of periderm differentiation,
have also been identified in NSCLP cases [123]. P300 is a multifunctional coactivator protein
that exhibits protein/histone acetyltransferase activity and is essential for normal embryonic
development and adult tissue homeostasis [124, 125]. Loss of p300 function in humans and
in mice leads to craniofacial defects, possibly due to altered WNT and TGF- signaling [124].
Craniofacial enhancer activity has recently been implicated in controlling facial
morphogenesis during development and influencing the incidence of cleft phenotypes in mice
[38, 126]. PBX2 rs3131300 is noted as a significant eQTL in the GTEx database with allelespecific differences in gene expression, the A allele being associated with higher expression
of PBX2 in whole blood. In turn, the alternate allele G, associated with NSCLP in our familybased analysis, may be predicted to decrease PBX2 expression. Although speculative, the
association of this decreased function variant in humans would be in agreement with the
observed effects of the reported murine Pbx regulatory module [59]. Bioinformatic analysis of
PBX1 rs6426870 also suggests potential functional effects with predicted alterations in 6
binding motifs, among them FOXD1, FOXF2, FOXK1, and FOXL1. Fox proteins have been
shown to regulate palate, facial cartilage and tooth development [80, 127-129]. Among these,
ample evidence exists suggesting that FOXE1 is associated with NSCLP risk, therefore
additional studies addressing the potential relationship between PBX1 and FOX genes are
warranted [114]. Additionally, in this study, NSCLP individuals had a higher frequency of the
PBX1 rs6426870 T allele, which was shown to be an eQTL associated with lower PBX1
expression in whole blood. This suggests that this variant might contribute to lower PBX1
expression, corroborating the findings in the mouse model [59]. Lastly, TP63 rs9332461
alternate allele G was predicted to have preferential binding to NKX2-1, a transcription factor
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in brain, lung and thyroid development [130, 131]. It was also located in enhancer mark-rich
regions in bone and muscle tissues. Of note, these predictions are only suggestive as they
obtained from gene expression data in whole blood, as there is currently a lack of a publicly
available embryonic craniofacial cell/tissue database.
Evidence of multiple gene-gene interactions was detected between the studied variants in
PBX1, PBX2, and TP63 with variants in other known cleft genes for which genotype data was
available in our NSCLP families [119, 132]. The majority of the interactions identified in the
present study were found in the NHW families, and included multiple markers in
PBX1/PBX2/TP63 with IRF6 rs2235371. Interactions between PBX1 and WNT9B were also
found in both NHW and Hispanic families. The IRF6 rs2235371 variant results in a valine to
isoleucine substitution at position 274 (V274I) of the protein and has been consistently
reported in association with NSCLP in many populations [119, 132-137]. Moreover, previous
studies have demonstrated the important role of IRF6, TP63 and WNT pathway genes and
their interactions in NSCLP and in craniofacial development [31, 43, 52, 75, 113, 129, 138141]. The results of this study reflect statistical probabilities of gene-gene interactions, and
yet revealed population-specific variant combinations in our NHW and Hispanic populations
that further highlight the heterogeneous nature of NSCLP with many genes with etiologic
and/or modifier roles contributing to the condition [4, 103, 104]. In the study by Ferretti et al.,
a Pbx-Wnt-Tp63-Irf6 regulatory module was proposed based on the observations that mice
lacking Pbx genes in the cephalic ectoderm exhibited fully penetrant cleft lip/palate and
disruption of the Wnt-p63-Irf6 regulatory network caused by suppression of midfacial
apoptosis [59]. In our study, this regulatory model in humans was mainly reflected on the
observed interactions between PBX1 with WNT9B and IRF6, and between PBX2 with IRF6
(Figure 7). Identification of potential biological interactions with purely statistical methods is
easily overinterpreted, and utilizing a family-based approach limits the methods available [96,
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142]. The observed statistical gene-gene interactions in the present study do not claim
biological interactions; rather, they support the already existing biological evidence for the
genes investigated [59].

Additional biological studies addressing the relevance of the

interactions identified in this study should further our knowledge of the complex genetic
architecture of NSCLP.
The results of this study provide the first evidence for a role of PBX1/PBX2, additional
evidence for the role of TP63, and support for the proposed PBX-WNT-TP63-IRF6 regulatory
pathway in the etiology of human NSCLP.

Studies focusing on identifying genes and

regulatory networks that when disrupted lead to NSCLP have the potential to advance
knowledge of the condition and directives for early diagnosis and prevention.
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CHAPTER 4: Fostering the face: the role of FOS in craniofacial
morphogenesis and nonsyndromic cleft lip and palate

Note: The information presented in this chapter is based on a manuscript prepared for
submission, for which I am first author. Additional coauthors include Bhavna Tandon, Qiuping
Yuan, Simone Menezes, Christian Urbina, George Eisenhoffer, Ariadne Letra and Jaqueline
Hecht.
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4.1 Introduction
Nonsyndromic cleft lip and/or palate (NSCLP) is the most common craniofacial birth defect,
affecting 1 in 700 live births and more than 135,000 newborns worldwide each year [4, 20]. It
results from the incomplete fusion of the facial prominences during development, which leaves
a gap in the lip, primary palate and/or the secondary palate [143]. In addition to the cleft, other
structural abnormalities including short philtrum, orbicularis oris muscle defects, nose
irregularities, disruptions in the alveolar bone and dental anomalies [4, 5, 144].

The

complexity of the lip and palatal defects and downstream effects require a multidisciplinary
approach that includes not only surgery but also hearing, speech and dental evaluations and
interventions [104, 145]. Despite improved intervention outcomes, affected individuals and
their families face significant financial and psychosocial burdens [146].

Studies of NSLCP suggest a multifactorial mode of inheritance, involving genetic and
environmental factors and their interactions [4]. Evidence for a genetic basis is supported by
observations that NSCLP aggregates in families, has a higher concordance rate in
monozygotic compared to dizygotic twins and presents an increased relative risk to individuals
with an affected first-degree relative [24]. Heritability is estimated to be around 70% although
varies by ethnicity [18, 147-149]. Currently, ~ 40 genetic risk loci have been associated with
NSCLP, which only explains aboout 30% of the heritability and, these results are not
consistent across populations [104, 150]. Thus, there is a critical need to broaden our
understanding of the genetic factors contributing to NSCLP.

In previous studies, we reported that CRISPLD2 was associated with NSCLP, which was
independently replicated in separate populations [151-154].

Knockdown of crispld2 in

zebrafish showed that loss of crispld2 caused severe craniofacial abnormalities [33, 155, 156],
which resulted from altered the migration of neural crest cells, a critical population of
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multipotent cells that give rise to the various tissues that make up craniofacial structures [41,
156]. Subsequently, morphant zebrafish were shown to differentially express seven genes
that comprised an in silico network, with Fosab, the zebrafish homolog of human FOS
identified. [33]. A positive association for FOS/rs1046117 in NSCLP families nominated FOS
as a candidate NSCLP gene [33].

FOS is known to play different roles, acting as a proto-oncogene, a transcription factor as part
of activating protein-1 (AP-1) and as an activator in the lipid synthesis pathway in the ER [157159]. In these roles FOS is involved in oncogenic processes such as tumor growth and
progression but also biological processes like proliferation, differentiation, epithelial-tomesenchymal transition and apoptosis [157-162]. Fos null mice display severe osteopetrosis,
impaired gametogenesis, abnormal hematopoiesis and behavioral changes (Agamemnon et
al 1994). Interestingly, craniofacial abnormalities such as a domed skull with a shorter snout,
absence of tooth eruption and a reduced neocortex are also observed in these studies [158,
160, 163, 164]. Data from a Fos-LacZ mouse show expression of Fos in orofacial tissues such
as the medial edge epithelium (MEE) of the palate, the dental papilla mesenchyme, the
periderm, and cells at the midline of the nasal septum [165, 166].

Additionally, Fos

immunostaining was present at the MEE just before elevation of the palatal shelves, the facial
epidermis, Meckel’s cartilage and the mesenchymal condensations that precede bone and
muscle formation in a rat model [167]. While these studies provide strong evidence that FOS
plays a role during craniofacial development, its specific contributions to mouth and palate
formation are not known. This study investigated the role of fos during craniofacial
development in zebrafish embryos to determine its potential involvement in craniofacial
morphogenesis and NSCLP.
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4.1 Materials and methods
Detailed methods of the techniques used in this study can be found in Chapter 2. Figure 7
provides a brief summary of the experiments.

Figure 7. Overview of experimental approach for fos study.

4.2 Results
4.2.1 Fos knockdown causes craniofacial abnormalities in zebrafish
To define Fos in craniofacial development, knockdown was performed using a translationblocking MO at the one-cell stage. As shown in Figure 8, morphant embryos displayed severe
abnormalities at 5 days post fertilization (dpf) with smaller head and eyes, cardiac edema,
abnormal yolk extension and missing swim bladder (Figure 8C) compared to uninjected (UIC)
and mismatch morpholino (MM) controls (Figure 8A and B). Bone and cartilage staining
revealed reduced and abnormally shaped jaw cartilages, including a diminished ethmoid
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plate, trabeculae and parachordal cartilages, reduced Meckel’s and palatoquadrate cartilages
and missing basibranchial cartilages (Fig. 8F-F’ compared to D-D’ and E-E’). Impaired
ossification was observed at the parasphenoid bone, branchiostegal rays and at
ceratobranchial arch 5, where there were missing or smaller pharyngeal teeth (Fig. 8F-F’
asterisks compared to D-D’ and E-E’). Also observed were fused occipital bones and
asymmetric neurocranial structures. These abnormalities were dose-dependent, with mild
ones resulting from 0.5ng MO injections and the most severe from 2ngs (Figure 9).

Figure 8. Fos knockdown caused craniofacial and dental abnormalities.

Figure 9. Phenotype severity increased with higher doses of fos morpholino.
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To evaluate pharyngeal/ branchial arch formation and visualize tooth development in more
detail, fos knockdown was performed in Tg(-4.9sox10:GFP), which allows for visualization of
the neural crest cells that form the arches. These embryos were stained with alizarin red to
examine mineralized tissues. At 5 dpf, pharyngeal arches (PA) 1 and 2 were the most affected
in the MO injected embryos, with 37% of embryos showing merged PA1 and PA2 or absence
of the structures (Figure 10C1, C2 compared to A and B). The arches also showed
disorganization, vertical and horizontal constriction and asymmetry. All morphant embryos
had intact but similarly abnormal PA 3-7. Additionally, complete mineralization of the fifth
ceratobranichal arch (CB5) was observed in 100% of the UIC and MM embryos (Figure 10F1F2 compared to D and E, Table 8), whereas mineralization was found in only 24% of fos
morphant embryos. Diminished mineralization persisted to 8 dpf, with the MO group still
showing only 68% mineralization (Figure 11). Smaller cleithrums and opercles (dermal
bones) were observed further indicating abnormal ossification.

Figure 10. Fos morphants showed abnormal arches and reduced mineralization at 5 dpf.
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The development of pharyngeal dentition was examined in detail from 5 to 8 dpf. At 5 dpf, 3
rows of pharyngeal teeth (one on each side –left and right pairs), termed 4V1, 3V1 and 5V1,
could be visualized in the UIC and MM injected controls, with 4V1 ankylosed/attached to the
perichondral bone of CB5 (Figure 11).

Figure 11. Zebrafish pharyngeal dentition at 5 and 7 dpf.

In comparison, MO embryos presented only 1 tooth on each side (4V1 only) which was often
smaller. In mild phenotypic morphants, 4V1 had attached/deposited bone around the nonmineralized CB5 cartilage, while severe phenotype morphants only showed 4V1 tips (Figure
12). At 6dpf, UIC and MM controls showed more bone deposition at CB5, with 4V1 still the
only tooth attached and 3V1 and 5V1 mineralizing towards CB5, but not yet attached. The mild
phenotypic morphants looked similar to those at 5 dpf with the tip of 3V1 observed, while the
severe morphants showed only the tip of 4V1 (Figure 12). By 7 dpf, UIC/MM showed 2
attached and 2 developing teeth, while the mild phenotypic morphants showed more bone
deposit around 4V1 at CB5. The severe morphants had unattached sets of 4V1 and 3V1
(Figure 12). Finally, at 8 dpf UIC and MM controls showed 3 sets of attached teeth and the
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tips of replacement tooth 4V2. Mild phenotype morphants resembled 5 dpf UIC/MM embryos
but with less mineralization at CB5. The severe morphants showed unmineralized CB5, no
attached teeth and the tips of 4V1, 3V1 and 5V1 (Figure 12). These findings are presented in
Table 8. Variability in left right symmetry of the teeth was seen in all groups, however the
morphants showed a greater discrepancy between the number of left and right teeth. These
observations together demonstrate abnormal tooth morphogenesis up to 8 dpf.

Figure 12. Developmental timeline of fos morphant dentition.
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Table 8. CB5 mineralization and pharyngeal tooth development is affected in fos
morphants. Pharyngeal teeth were counted in embryos at 5-8 dpf and tabulated the
developmental timeline they appear (4V first and 4V2 last). While UIC and MM embryos
developed most of the pharyngeal teeth, fos morphants either failed to develop certain rows
of teeth or showed asymmetry in their formation.

Developmenta
l day

UIC

MM

MO

Tooth Id.
Left
CB5

Right

Left

100%

Right

Left

100%

Right
24%

4V

100

100

100

100

91

93

3V

89

78

73

54

10

2

5V

67

0

60

33

7

0

5 dpf

CB5

100%

100%

47%

4V

100

75

100

100

100

100

3V

100

75

75

75

47

47

5V

100

75

75

50

27

37

6 dpf

CB5

7 dpf

100%

58%

4V

91

91

100

100

100

100

3V

90

73

100

100

75

50

5V

73

73

100

100

25

17

4V2

64

55

88

88

0

0

CB5

8 dpf

100%

100%

100%

69%

4V

100

100

100

100

93

100

3V

100

86

100

100

69

66

5V

86

86

100

100

41

45

4V2

71

86

80

100

7

10
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Figure 13. Fos morphants had abnormal facial morphology with a keyhole shaped mouth.

4.2.2 Fos morphants have abnormally-shaped mouths and craniofacies
The most striking abnormality was a keyhole-shaped mouth observed in the majority of
morphant embryos (Figure 13) and resembled a previously reported hypoplastic upper lip or
a median cleft observed in Xenopus embryos [168, 169]. zFACE, a novel tool to evaluate
facial shape in zebrafish embryos was used to quantify the changes in facial morphometry in
fos morphants and analyzed using feature-focused, PCA and shape analyses. Differences in
zFACE measurements were first evaluated to determine which facial dimensions were
affected as a result of fos knockdown. Univariate ANOVA revealed that 27 of the 39 zFACE
measurements were significantly different in the morphant embryos compared to both UIC
and MM groups (p < 0.0013). These included 15 parameters involving the oral cavity, 5
horizontal axis measurements, 5 midface angles, and 2 facial area measurements (Figure
14, 15). Fos morphants had a decreased mouth width but increased mouth height (p < 0.0001
for both) compared to the UIC/MM controls. The keyhole-shaped oral cavity was reflected by
the increased chelion, crista philtri and labiale inferius and decreased labiale superius angles
(p < 0.0001 for all), (Figure 14). Facial width, olfactory distance, neuromast width and chin
width were also significantly reduced in the morphants reflecting a horizontally narrowed face
(p < 0.0001).
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Figure 14. Graph of two mouth angles significantly altered in fos morphants at 5 and 6 dpf.

In contrast, measurements that involved the olfactory epithelium and neuromasts in the
midface, such as left and right olfactory to mouth and neuromast angles were significantly
increased (p < 0.001), reflecting abnormal midface dimensions. Interestingly, facial height (p
= 0.98), mouth to chin distance (p = 0.60), neuromast height (p = 0.97) and mid olfactory to
chin height (p = 0.23) were unchanged after fos knockdown indicating unaffected vertical axis
dimensions. Analysis at 6 dpf showed similar results suggesting that developmental delay
due to toxicity does not contribute to these differences in the morphant embryos.

Figure 15. Summary of altered
zFACE
dimensions
in
fos
morphants.
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Table 9. zFACE analysis results for all morphometric measurements.
Morphometric feature
Width
Height
Olfactory Distance
Upper Lip Width
Lower Lip Width
Mouth Width
Olfactory to Mouth
Olfactory to Mouth 2
Difference
Olfactory to Mouth 3
Chin Width
Mouth to Chin
Alternate Height
Mouth Height
Neuromast Angle 1
Neuromast Angle 2
Difference
Neuromast Height
Neuromast Width
Mid Neuromast Width
Avg Length Olf. to mouth
Area Top
Area Bottom
Area Combined
Mid Olfactory to Chin height
Mouth Area
Mouth Perimeter
Libiale Superius Angle
Chelion Left Angle
Chelion Right Angle
Chelion Diff
Labiale Inferius Angle
Crista Philtri Left Angle
Crista Philtri Right Angle
Crista Philtri Diff
Labiale Superius Mid Angle
Labiale Inferius Left Angle
Labiale Inferius Right Angle
Labiale Inferius Diff

ANOVA

Tukey's multiple comparison test
UIC vs.
UIC vs.
fosMM vs.
fosMM
fosMO
fosMO
ns
****
****

Change
in MO
↓

ns

ns

ns
ns

ns

ns

ns
ns

ns

ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns
ns

****
***
****
****
****
****
ns
****
****
ns
ns
****
****
****
***
ns
****
****
ns
***
****
****
*
ns
****
****
****
****
****
****
****
****
****
****
****
****
ns

****
****
****
****
***
****
ns
****
****
ns
ns
****
****
****
**
ns
****
****
ns
*
****
****
ns
*
****
****
****
****
****
****
****
****
**
****
****
****
*

↓
↑
↑
↓
↑
↑
↓
↓

↑
↑
↑
↑
↓
↓
↓
↓
↓

↓
↓
↑
↑
↑
↓
↑
↑
↑
↓
↑
↑

**** p <0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05
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Principal component analysis (PCA) of the total embryo group showed that the first principal
component (PC1) explained 41% of the variability. The libiale superius angle, chelion right
angle and crista philtri left angle measurements significantly loaded (eigenvector ≥ 0.30) into
PC1 driving and explaining most of the variation. Logistic regression, with group as the
dependent variable, and PC1 score as the independent variable, showed that PC1 score could
be used to predict whether an embryo is a control or fos morphant, but could not distinguish
between the UIC and MM controls (UIC and MO comparison p = 0.001; MM and MO
comparison p < 0.0001; UIC and MM comparison, p = 0.54).

Figure 16. PC plot showed fos morphants separating from both controls and shape changes
along PC1.
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Procrustes transformed landmark analysis was additionally used because it removes variation
in size, rotation and scale and aligns landmarks to a principal axis in order to compare only
shape.

Both PCA and discriminant function analysis (DFA) were performed with these

superimposed landmarks (Figure 16 and 17). PCA of this scaled data was similar to the
untransformed zFACE measurements PCA (Figure 16). Shape changes along PC1 were
visualized with transformation grids with lollipop graphs (showing vectors of change) and
wireframe diagrams and showed changes in landmarks around the mouth and midface,
resulting in altered mouth shape and facial width (Figure 16). DFA confirmed that fos
morphants had a significantly different mean face shape compared to both UIC and MM
controls (Figure 17). Changes in 21 landmarks were observed between MO group with either
UIC or MM controls and these changes were reflected in the wireframe diagrams showing a
narrower face shape with an O-shaped mouth (Figure 17). The changes in Procrustes
distance was significant (p < 0.001). These results together provide parallel evidence that fos
knockdown significantly alters orofacial morphology.

Figure 17. DFA results showed significantly different face shape in fos morphants.
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4.2.3 Human fos mRNA rescues morphant phenotype
To test the specificity of the morphant phenotype to fos knockdown, an in vitro synthesized
human FOS (Hu-FOS) mRNA was co-injected with the fos morpholino to rescue morphant
abnormalities.

Brightfield and DAPI-stained rostral images showed that Hu-FOS RNA

significantly rescued the gross abnormal morphology, abnormal facial phenotype, including
the size of the head and eyes, as well as finer facial features (Figure 18). While 82% of fos
morphants had an abnormal mouth and face, human FOS mRNA co-injection rescue
decreased abnormal embryos by 45%. Overexpression of human-FOS RNA in zebrafish
embryos also caused severe abnormalities, including extended lower jaw and cyclopia.
Morphometric analysis was not performed in the overexpression group because the
anatomical facial landmarks were not present.

Figure 18. Human FOS mRNA rescued facial abnormalities associated with fos knockdown.
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ZFACE analysis of UIC, MO and rescue groups identified 11 features that were rescued by
co-injection of Hu-FOS (all 3 olfactory to mouth angles, neuromast angle 1, both chelion
angles, labiale superius mid angle and both labiale inferius angles (p > 0.0013 comparing UIC
and rescue groups). Thirteen additional features displayed a more normal, intermediate
phenotype in the rescue group, but did not meet our statistical criteria for rescue (p < 0.0013
in UIC vs rescue comparison). The rescue embryos in this category were significantly different
compared to UIC but they were also different compared to MO in measurements of facial
width, olfactory distance, mouth width, chin width, mouth perimeter and others.

Figure 19. PC plot results confirmed the rescue group was more similar to controls.

Joint PCA of the rescue experiments together with the MO, MM and UIC data obtained for the
initial morphometric analysis showed overlap of the rescue group with the UIC and MM groups
when confidence ellipses were drawn in the plot (Figure 19). To determine face shape
changes that were due to fos knockdown and concomitantly rescued by fos mRNA, DFA was
used to compare the morphant and rescue groups as well as the rescue and control groups.
When comparing rescue and MO, landmarks on the edges of the mouth as well as the top
and middle neuromasts had the largest vectors of change, with the rescue embryos showing
more normal mouths and wider midfaces (Figure 20). Comparing the rescue with the UIC
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showed that rescue embryos had a less crescent shaped (more oval) mouth and narrower
chin (Figure 20). Overall, these results demonstrate that the fos morphant phenotype,
especially the abnormal mouth shape, is specific to fos knockdown in these embryos, can be
rescued by human FOS mRNA co-injection, and not caused by any off-target effects of the
morpholino or the injection process itself.

Figure 20. DFA showed the rescue group had a more normal average face shape.

4.2.4 Fos CRISPR/Cas9 F0 mutants recapitulate morphant craniofacial
phenotype at 5 dpf
To generate a stable loss-of-function model for fos, CRISPR F0 mosaic mutants were
generated using CRISPR/Cas9. Two single guide RNAs (sgRNAs) in exons 1 and 4 of the
fos gene were designed to delete the entire fos coding region. F0 overall phenotypes ranged
from mostly normal embryos to embryos with heart edema, smaller head, and smaller curved
body axis, similar to morphant phenotypes. Genotyping revealed efficient mosaic
mutagenesis in these F0s with most embryos showing a deletion of approximately 1500bp in
the fos coding region.
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UIC

fosF0

Figure 21. CRISPR/Cas9 mutants recapitulated the morphant phenotype.

The F0s were analyzed using bone and cartilage staining and zFACE morphometrics to
determine if the CRISPR-induced genetic lesions recapitulated the morpholino knockdown
phenotype. F0s showed reduced and abnormal jaw cartilages (Figure 21) as well as a range
of dysfunctional facial features similar to the morphants. ZFACE measurement analysis
showed 16 out of 39 significant changes after Bonferroni correction (Student’s t test, p <
0.00128).

These included olfactory distance, mouth width, olfactory to mouth angles,

neuromast angles, mouth perimeter and labiale inferius and labiale superius mid angles (p <
0.00128).

Nine additional parameters showed a trend (p < 0.05) but did not meet the

Bonferroni corrected significance threshold.
A combined PCA plot (Figure 21) showed clustering of the F0s in the same area as the
morphants, further confirming that the majority of mutants display similarly abnormal facies as
the morphants. Only a few F0 embryos mapped to the same region as the controls likely
related to mosaicism in the fos F0 mutants. Interestingly, DFA comparison of the F0 and
morphant embryos showed only a few differences, with the overall mean face shape being
very similar.
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4.2.5 Cranial neural crest cells are reduced in fos morphant and mutant
embryos
To further understand the mechanisms by which fos regulates craniofacial development,
cranial neural crest cell (CNCC) populations were examined because craniofacial
development is highly dependent on the correct formation, migration and differentiation of
these cells [41]. The transgenic line Tg(-4.9sox10:EGFP) that contains GFP downstream of
a sox10 promoter/enhancer element and drives expression of GFP in pre-migratory and
migrating NCCs was used in these experiments [170].

Figure 22. CNCC populations were altered in fos morphants and mutants.

As shown in Figure 22, NCC development and migration were unaffected in the morphants
compared to the controls at 24 hours post fertililization (hpf) (p = 0.27). However, at 48 hpf,
significant differences were found in both the number and migration pattern of CNCCs in the
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morphants compared to UICs (quantified fluorescence, p < 0.0001). At 3 dpf the morphants
showed reduced CNCCs compared to both the UICs and MMs (p < 0.0001 and p = 0.002
respectively). These differences became more pronounced at 5 dpf, as evidenced by a
significant decrease of sox10.GFP fluorescence in morphants compared to controls (p <
0.0001) (Figure 23). Similar results were observed when CRISPR guides were injected into
this transgenic line, with fos F0 mutants showing both reduction and abnormal migration of
neural crest cells at 48 hpf and 5 dpf (Figure 23, bottom panel). These alterations were also
confirmed by quantification of average fluorescence (p < 0.0001 for both developmental time
points). Fos morphants and fos F0 mutants were not significantly different at any of the time
points assessed.

Figure 23. Sox10 expression was significantly reduced in fos morphants and mutants.
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4.3 Discussion
Fos, a proto-oncogene, has a known but poorly defined role in embryonic development and
specifically, craniofacial development [158-160, 163]. In this study, we show that reduction or
absence of fos in zebrafish embryos resulted in a wide array of craniofacial phenotypic
abnormalities, including a keyhole shaped mouth, abnormal face shape and missing or
smaller teeth. These gross anomalies resulted from abnormal skeletal and cartilage elements,
caused by dysregulation in specific cranial neural crest (CNCC) populations that are
necessary for normal facial and oropharynx patterning. This study provides new information
about the specific contributions fos makes to vertebrate craniofacial development.
Previously, we identified fos in a network of differentially expressed genes in a crispld2
zebrafish model of orofacial clefts, which was confirmed by association with NSCLP in a
family-based dataset [33]. Different genetic approaches, employing fos morphants and F0
mutants, were used to determine the effects of fos perturbation in craniofacial morphogenesis.
Starting at 48 hpf, fos morphants and mutants had smaller head and eyes, cardiac edema,
abnormal yolk extension and missing swim bladder. Close analysis of bone and cartilage
showed smaller ethmoid plate, reduced Meckel’s and palatoquadrate cartilages and missing
basibranchial cartilages. The most dramatic phenotype observed was a keyhole-shaped
mouth at 5 and 6 dpf, similar to a hypoplastic lip phenotype observed in a zebrafish model of
orofacial clefts [169]. Using zFACE morphometrics, regional facial alterations were identified
in the mouth, olfactory pits (nasal cavities) and midface neuromasts among other features,
strongly supporting the role of fos in the morphogenesis of these structures. Furthermore,
additional analyses with zFACE data showed the most robust changes resulting from fos
disruption were to the oral cavity and midface. Interestingly, changes in the dimensions of the
maxillae and nasal pits have been reported to correlate with the development of cleft lip and
palate in mice [171-173].

Additionally, human morphometric studies have shown facial
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differences in individuals predisposed to orofacial clefts as well as their unaffected relatives,
including differences in the upper lip, philtrum and nasolabial angles [12, 174-177]. These
morphometric differences observed in mice and humans, which are similar to alterations in
facial structures in the current zebrafish model, further support the role of fos in the etiology
of orofacial clefts. Additionally, because zFACE uses similar anatomical landmarks to those
in mouse and human studies, it offers comparability across different species, an important
advantage for a better understanding in this area of research.
Rodent models to understand Fos function have shown that Fos is expressed in some
orofacial tissues such as the medial edge epithelium (MEE) of the palate, the dental papilla
mesenchyme, the periderm, and cells at the midline of the nasal septum [166, 167] Given
this expression pattern, it is not surprising that fos knockout mice develop craniofacial
abnormalities such as a domed skull, shorter snout and abnormal maxillas, mandibles and
dentition [163, 164].

Data from the zebrafish model in this study recapitulates these

craniofacial abnormalities, signifying the conserved nature of Fos function across all
vertebrates. Even though we observed reduced, and not increased bone like the osteopetrotic
fos null mice, our results are not necessarily in contradiction because fos has also been shown
to control endochondral ossification and is highly expressed in osteoblast precursors at critical
stages when mineralization takes place [158].

Additionally, an avian embryonic model

showed that viral injection of fos caused chondrodysplasia with a delay in chondrocyte
differentiation and subsequent ossification, further signifying that precise levels of fos are
necessary for correct skeletal development [178]. The decreased ossification we observed in
the head could be a consequence of abnormal endochondral, periochondral and direct
ossificiation because jawbones, pharyngeal bones and dermal bones were all affected.
Fos null mice also have smaller teeth that fail to erupt and form roots [163]. Even though the
process of tooth eruption in mice is different from pharyngeal tooth attachment to a
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mineralized ceratobrachial arch 5 (CB5) in zebrafish, zebrafish fos morphants also had
abnormal tooth development with marked delays in formation, abnormal tooth size, shape and
number, as well as increased asymmetry between left and right sides of the pharyngeal jaw.
The teeth that did form by 8 dpf were either beginning to attach around unmineralized CB5 or
not attached at all, likely impacting the functionality of the pharyngeal jaw. Together, the
skeletal and dental abnormalities observed in fos morphants/mutants parallel the
abnormalities seen in fos null mice and these findings together enhance our understanding of
the importance of fos in the development of these structures [163, 164, 179-181]
The abnormalities observed in both craniofacial and dental morphogenesis pointed to a
common developmental program involving the cranial neural crest cells (CNCCs).
Craniofacial development in vertebrates is highly dependent on the correct formation,
proliferation, differentiation and migration of NCCs [41]. Transgenic zebrafish lines labeling
premigratory and migrating NCCs were used to show that both fos morpholino knockdown
and deletion by CRISPR/Cas9 caused a reduction in cranial NCCs starting at 48 hpf. This is
a critical time point during which the CNCCs populate the seven pharyngeal arches of the
zebrafish viscerocranium and the ethmoid plate in the neurocranium [182]. They begin to
form the facial skeletal elements by adopting chondrocyte and osteoblast cell fates [182]. The
reduction of CNCCs likely led to the abnormal arches observed starting at 3 dpf, and the
abnormal jaw skeletal elements observed at 5 dpf. We have previously demonstrated that
crispld2 knockdown affects the viability and migration of NCCs in the early zebrafish embryo
[155, 156]. However, fos did not affect the early migration of NCCs, which starts around 14
hpf [156]. The loss of CNCCs observed in the current study could result from disruption of
several cellular process that fos has been shown to regulate [158, 159, 165, 183]. For
example, perturbation of fos could disrupt NCC populations by impacting the function of AP1,
which regulates gene expression to control cell proliferation, survival and migration [183]. In
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trophoblasts, expression of fos contributes to the robust activity of AP1 regulated gene
expression [183]. Additionally, fos knockdown in vitro inhibits cell migration and invasion while
inhibiting proliferation and promoting apoptosis, while fos overexpression interferes with the
equilibrium of cell proliferation and induces transformation and tumor formation [184]. In c.
elegans, fos is also a cell autonomous regulator of cell invasion, a process critical for many
cell types and also NCCs, as they have to invade through extracellular matrix, mesoderm and
migrating endothelial cells to reach their destination making their motility and invasive ability
crucial [185, 186]. The exact cause of loss of CNCCs in fos morphants/mutants warrants
additional study.
The strengths of using zebrafish include optically clear embryos, which allow the observation
of biological processes, and ease of genetic modifications using morpholino and
CRISPR/Cas9 technology [182, 187]. While other studies have relied on lateral and ventral
imaging to assess zebrafish craniofacial development, these orientations miss critical facial
phenotypic information. In contrast, the rostral mounting technique used in this study enabled
detailed assessment of facial structures for a more direct comparison to human phenotypes.
Additionally, specific alterations of facial dimensions were captured by zFACE, providing an
unbiased assessment of the changes in morphants and mutants and lack of changes in
rescued embryos. This novel morphometric program will be highly advantageous for studying
the effects of genetic manipulation of other craniofacial genes.
In conclusion, the results of this study demonstrate that fos is critical for NCCs and craniofacial
development. Importantly, absence of fos leads to abnormal bone and cartilage development,
causing a mouth shape that resembles an orofacial cleft phenotype. Moreover, the findings
suggest that perturbations in genes that regulate NCCs, such as fos, can have a detrimental
effect on NCC-derived tissues and alter normal craniofacial development, thereby contributing
to NSCLP. Further work is needed, in both zebrafish and humans, to identify other genes and
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pathways by which fos is regulating craniofacial development. Our study also provides a
model to test putative genes associated with NSCLP in vivo, explore their molecular
mechanism in early orofacial development and identify new targets that can be tested in
human NSCLP populations.
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CHAPTER 5: The role of regulatory variants in FZD6 and interacting genes in
nonsyndromic cleft lip and palate

Note: The information presented in this chapter is based on a manuscript being prepared for
submission, for which I am first author. Additional coauthors include Syed Hashmi, Susan
Blanton, Bhavna Tandon, Brett Chiquet, George Eisenhoffer, Ariadne Letra and Jaqueline
Hecht.
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5.0 Introduction
As part of our ongoing genetic studies, GWAS in a large multiplex NSCLP family identified a
linkage region harboring rs138557689, a functional noncoding single nucleotide variant (SNV)
upstream of the frizzled-6 (FZD6) gene which segregated with NSCLP in all the affected
individuals in the family [65]. This SNV created a novel TF binding site resulting in an 80%
reduction in luciferase reporter activity and suggesting that it affects FZD6 expression.
Interestingly, Fzd6 null mice have claw and hair patterning defects while Fzd3/Fzd6 double
knockout animals display midbrain morphogenesis defects [188-190].

Knockdown and

overexpression of fzd6 in zebrafish both led to severe craniofacial abnormalities confirming
that tightly regulated fzd6 expression is necessary for correct craniofacial development [65].
Collectively, these studies implicated FZD6, a receptor in the Wnt pathway, as an important
NSCLP candidate gene.
Wnt signaling is one of the key pathways in craniofacial development, directing migration of
NCCs and subsequent growth and fusion of the facial prominences[49]. Wnt pathway genes
are highly expressed in both the ectoderm and underlying mesenchyme of the facial
prominences and palatal shelves. Wnt activity in mammals is high in areas of rapid growth,
specifically in lateral regions such as the maxilla, and is low or absent in the frontonasal
prominence [49, 52]. In order to transmit Wnt signaling, the FZD receptor requires the
coupling of either co-receptor low-density lipoprotein-related protein 5 (LRP5) or LRP6, which
is inhibited by dickopff (DKK) family members [191]. Intriguingly, lrp6 is expressed in the
murine orofacial primordia and null mutant embryos show reduced Wnt signaling, bilateral
cleft lip and mandible defects [75]. Recently, a mutation in LRP6 was identified in a multiplex
NSCLP family with tooth agenesis [74]. LRP5 mutations in humans are associated with
syndromic craniofacial bone abnormalities and zebrafish lrp5 morphant and mutant models
show abnormal craniofacial cartilage phenotypes [71-73]. During early development, the
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head and other anterior structures form under a gradient of increased Dkk1 expression and
decreased Wnt signaling [76]. Dkk1 null mice display severe craniofacial abnormalities and
completely lack facial structures, while overexpression of Dkk1 in Wnt reporter mice causes
altered Wnt activation pattern in the developing craniofacies and affects the dimensions of the
facial prominences [76, 77] [52]. Together, these studies show that the interacting partners
of FZD6 are also critical for normal craniofacial development and perturbation of their
expression leads to orofacial phenotypes, making them important NSCLP candidate genes.
Results from GWASs of complex disorders (adult complex disorders and birth defects) show
that the majority of risk variants are located in the noncoding regulatory landscape of the
genome [192]. Importantly, this finding is also observed in NSCLP, where the majority of
GWAS “hits” also fall in noncoding regions [35, 40, 150, 193, 194]. These regions may harbor
functional genetic elements, which are often characterized by open chromatin structures,
allowing the binding of transcription factors (TF) and coactivator proteins to regulate gene
expression [37]. Since variation in these regions contributes to the heritability of NSLCP, their
functional characterization is a new and exciting research focus that may uncover missing
contributory genetic variation [35, 40]. In the current study, putative noncoding variants
upstream of FZD6, LRP5, LRP6 and DKK1 were prioritized using bioinformatic evidence and
assayed for functionality in cell-based and zebrafish assays before being tested for
association, alone and in combination, in a large and well-characterized NSCLP family
dataset.
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5.1 Materials and methods
A detailed description of methods used can be found in Chapter 2. A workflow of the
methodology is presented in Figure 24.

Figure 24. Approach to identify and test noncoding variants in FZD6 and related genes.
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5.2 Results
5.2.1 Twenty one putatively functional variants prioritized for study
Our bioinformatic prioritization approach identified 21 potentially functional SNVs in all four
genes. Information on the number of variants that were evaluated using the prioritization
method is presented in Table 10. Interestingly, the majority of the candidate functional SNVs
were predicted to bind TFs that have been implicated in craniofacial development, such as
AP2α, RARα, and GRβ [40, 195-198]. Table 11 lists the minor allele frequency (MAF), basewise genomic evolutionary rate profiling (GERP) scores and predicted TFs for the selected
SNVs.

Table 10. Bioinformatic prioritization results

SNVs IDed
Gene Chrom dbSNP

Annotation
Pos
In silico
Prioritized
GERP
TF
SNVs
and open
binding
chromatin

Total 5'

GWAVA

VEF

total

variants

SNPs w
info

Modifier Promoter

FZD6

8

1801

227

72

227

57

13

9

6

LRP5

11

8979

200

57

200

56

12

6

5

LRP6

12

8595

267

69

267

102

23

12

5

DKK1

10

447

385*

101

427

248

18

6

5
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Table 11. Details of selected variants and predicted TFBSs

FZD6

LRP6

LRP5

DKK1

Variant

MAF

GERP

rs75892544
rs1522711
rs80084586

0.06
0.45
0.46

1.3
1.08
1.5

rs827525

0.02

0.9

rs74949239
rs827526
rs115369160
rs7136900

0.03
0.25
0.02
0.28

2.1
1.8
1.76
1.04

rs79239491

0.03

3.53

rs7302808
rs7136380
rs58529904
rs4988325
rs312009
rs77394830
rs4988327
rs7069912
rs114971851
rs114205486
rs75526820
rs1528879

0.47
0.26
0.04
0.17
0.19
0.03
0.03
0.12
0.02
0.01
0.03
0.07

2.61
1.36
2.95
0.785
1.19
0.937
0.937
1.89
1.54
2.71
2.08
2.17

In Silico Prediction
Ancestral
Alternate
-RARα, RARß, c-Myc
GRß
FoxP3
-AP-2α
MyoD, c-Myc, AP-2,
p300
RXRα
-AP-2, Sp1
p300
AP-2, RXRα
AP-2α
NF-kappaB, GRß
GRß, Pit-1a
c-Fos, c-Jun
Sp1, Pax5, GR-α,
C/Ebalpha
AP-2
-c-Myb
Sp-1
AP-2α, RARα
-RARα, RARß
NF-1
VDR, RARα, GR
AP-2, NF-1, AP-2α
RARß
GR
c-Myb
C/EBPα
-RXRα
c-Fos, c-Jun
MEF-2A
GR
Pit-1a, IRF-1, IRF-2
GRα
HNF-1
Sp1, Pax-5
GRα, Pax-5
Foxp3

5.2.2 Protein-DNA binding assays showed allele-specific effects for ten
variants
SNVs prioritized using in silico tools were tested for allele-specific binding with electrophoretic
mobility shift assays (EMSAs). Screening of the 21 putatively functional SNVs identified 10
variants that displayed allele-specific binding patterns: 1 variant in FZD6, 3 variants in LRP5,
3 in LRP6 and 3 in DKK1 (Table 2, Figure 25A). A summary and results for LRP6 rs7136380
are presented in Figure 25. These results suggested that 10 variants created allele-specific
protein binding sites giving them the potential to affect gene transcription and expression.
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5.2.3 Luciferase assays identified six variants with allele-specific effects on
expression
Cloned reporter constructs containing each variant and flanking region in front of the
respective gene promoter driving luciferase expression were transfected into 3 different cell
lines in order to examine allele and cell-specific influences on gene expression.

Figure 25. Results for LRP6 rs7136380 showed allele-specific banding and luciferase
expression.

Interestingly, while FZD6 rs75892544 did not show an effect in 293T cells, both HeLa and
MCF7 cells showed that the alternate allele significantly increased promoter activity (p= 0.02
for both). The LRP5 promoter and experimental variant constructs all showed comparatively
low luciferase expression in all 3 cell lines. Only one LRP5 variant, rs4988327, showed an
effect: the ancestral allele led to higher promoter activity in 293T cells and this effect was
replicated in the MCF7 cells (p= 0.02 and p= 0.03 respectively). For LRP6, 293T cells showed
an effect for all 3 SNVs: the rs115369160 alternate allele reduced activity (p= 0.005), the
alternate rs7136900 allele reduced activity (p= 0.0004), and the alternate rs7136380 allele
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increased activity (p= 0.03) (Figure 25). HeLa and MCF7 cells only replicated this effect for
rs7136380 (p= 0.0003 and p= 0.001 respectively). All three DKK1 variants showed an allelespecific effect in 293T cells. The rs7069912 alternate allele showed higher activity than the
ancestral (p= 0.002), for rs114205486 the alternate allele showed lower activity (p=0.001) and
for rs114971851 the alternate allele was significantly lower than the ancestral (p=0.00002).
For rs7069912, the alternate allele showed higher activity in the HeLa cells but the p value
was marginal (p=0.050) and in MCF7 cells the alternate allele led to lower activity (p=0.001).
Both other SNVs showed consistent effects in HeLa and MCF7 cells. These differences in
the various cell lines for each study variant were expected for noncoding variation, which is
known to have cell-specific effects [35, 37]. A summary of the findings from the EMSA and
Luciferase assays is shown in Table 12.

Table 12. Summary of EMSA and luciferase assay results for prioritized variants.
Luciferase Assay
293T
HeLa
MCF7

Gene

Variant

EMSA

FZD6

rs75892544

Y

N

Y

Y

LRP6

rs115369160

Y

N

N

N

LRP6

rs7136900

Y

Y

N

N

LRP6

rs7136380

Y

Y

Y

Y

LRP5

rs58529904

Y

N

N

N

LRP5

rs4988325

Y

N

N

N

LRP5

rs4988327

Y

Y

N

Y

DKK1

rs7069912

Y

Y

Y

Y

DKK1

rs114971851

Y

Y

Y

Y

DKK1

rs114205486

Y

Y

Y

Y
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5.2.4 Establishment of timeline for mouth development and β-catenin
expression
Time course analysis was performed utilizing two stable Wnt reporter lines, Tg(7xTCFXla.Siam:nlsmCherry)ia4 and Tg(7xTCF-Xla.Siam:GFP)ia4 to establish regional and temporal
Wnt activation in zebrafish [92]. These transgenic reporter animals have 7 tcf binding sites
driving mcherry or gfp expression, which allow for the visualization of activated β-catenin Wnt
signaling during embryonic development, making these lines β-catenin biosensors [92].
Reporter embryos were collected from 1 to 7 days post fertilization (dpf), fixed in 4% PFA,
stained with DAPI to visualize the nuclei of each cell, and then mounted in 1% agarose for
confocal imaging. The novel rostral mounting technique developed in the Eisenhoffer lab was
used to capture important facial features such as the neuromasts, olfactory pits, oral cavity
and jaws.

Results showed robust β-catenin Wnt signaling in the craniofacial region,

specifically in the developing oral cavity by 3 dpf (Figure 26). Expression was also observed
in the developing brain starting at 24 hpf through 7 dpf. A summary of the results for embryos
48 hpf to 5 dpf, where the gfp channel indicates β-catenin activation (bottom panel) and the
merged DAPI and gfp channels image visualize facial structures where expression is

Figure 26. β-catenin activation during orofacial development in zebrafish embryos.
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observed (top panel) is shown in Figure 26. This pattern was observed up to 7 dpf and these
results were also confirmed using the same reporter attached to a different fluorophore (the
mCherry line with the nuclear localization signal).

5.2.5 Knockdown of FZD6 and related genes caused similarly abnormal facial
phenotypes
Morpholino knockdown was performed for each study gene to determine its importance to
craniofacial development, facial morphogenesis and to identify facial structures affected by
perturbations in gene expression. Knockdown of all four genes altered the pattern of β-catenin
expression in the head starting at 3 days post fertilization, however a significant difference in
β-catenin levels was not observed at this timepoint (Figure 27). Evaluation of craniofacial
morphology at 5 dpf using zFACE revealed ten altered facial measurements after fzd6
knockdown, 17 after lrp5, 23 after lrp6 and 26 after dkk1 knockdown. Intriguingly, 7 facial
dimensions were commonly atlered after all four gene knockdowns and included mouth
height, mouth width, and various oral cavity angles (p < 0.0013), shown in Table 13).
Measures of differences between left and right side facial angles were not different in any of
the knocdowns.

Figure 27. Knockdown of FZD6 and related genes caused abnormal faical phenotypes.
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Table 13. ZFACE morphometric results in FZD6, LRP5, LRP6 and DKK1 morphants.

zFACE feature

UIC vs. FZD6

UIC vs. LRP6

UIC vs. LRP5

UIC vs. DKK1

Width
Height
Olfactory Distance
Upper Lip Width
Lower Lip Width
Mouth Width
Olfactory to Mouth
Olfactory to Mouth 2
Difference
Olfactory to Mouth 3
Chin Width
Mouth to Chin
Alternate Height
Mouth Height
Neuromast Angle 1
Neuromast Angle 2
Difference
Neuromast Height
Neuromast Width
Mid Neuromast Width
Average Length Olfactory to
mouth
Area Top
Area Bottom
Area Combined
Mid Olfactory to Chin height
Mouth Area
Mouth Perimeter
Libiale Superius Angle
Chelion Left Angle
Chelion Right Angle
Chelion Diff
Labiale Inferius Angle
Crista Philtri Left Angle
Crista Philtri Right Angle
Crista Philtri Diff
Labiale Superius Mid Angle
Labiale Inferius Left Angle

**
ns
****
ns
ns
****
****
****
ns
****
ns
ns
*
****
*
***
ns
**
**
ns
ns

****
****
****
ns
****
****
****
***
**
****
*
**
**
***
**
****
ns
***
****
****
****

ns
ns
ns
ns
ns
**
ns
ns
ns
ns
ns
ns
ns
***
ns
ns
ns
ns
ns
**
ns

****
***
****
ns
ns
****
****
****
ns
****
***
**
**
**
****
****
ns
****
****
***
****

ns
*
ns
ns
ns
****
ns
ns
ns
ns
****
****
****
****
****
****

****
***
****
*
ns
****
ns
ns
ns
ns
****
****
****
ns
****
****

ns
ns
ns
ns
**
ns
ns
ns
ns
ns
***
**
**
ns
****
****

****
****
****
ns
ns
****
**
**
**
ns
****
****
****
ns
****
****

Labiale Inferius Right Angle
Labiale Inferius Diff

****

****

***

****

ns

ns

ns

ns

* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001
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Figure 28. Morphometric results showed common alterations after knockdown of fzd6, lrp5, lrp6
and dkk1.

Figure 29. DFA results showed that all morphants had a significantly different face shape
compared to controls but a similar face shape compared to each other.
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5.2.6 Small molecule inhibition and activation of WNT signaling alters facial
phenotype
Two small molecule Wnt modulators, the antagonist IWR-1 and agonist BIO were used to
treat zebrafish embryos starting at 24 hpf up to the time of collection in order to examine the
effects of β-catenin inhibition and activation on facial morphogenesis. Both treatments altered
the facial and mouth pheontype at 3 and 5 dpf (Figure 30A). Importantly, these phenotypes
were similar to the morpholino knockdowns, displaying abnormally oval and elongated oral
cavities. These experiments were repeated in the Wnt reporter lines and showed a significnat
reduction of β-catenin activation in the craniofacial region after IWR treatment compared to
both the untreated control (UTC) and DMSO treated control (p = 0.0002). BIO treamtment,
on the other hand, led to an increase β-catenin activation, however, this difference was only
singificant in the UTC comparison (p = 0.01). These results further indicated that perturbation
of β-catenin activation results in craniofacial and mouth abnormalities, similar to knockdowns
of the study genes, which code for receptors upstream in the signaling of this pathway.

Figure 30. Wnt drugs altered facial phenotype and β-catenin activation in the oral cavity. A. Both
IWR and BIO treamtnent altered the face at 3 and 5 dpf. B. IWR led to a decrease in beta catenin while
BIO led to an increase.

88

5.2.7 Transgenic reporter zebrafish assays supported functionality of four
variants
Zebrafish were generated to further test variants showing functionality in the cell based assays
in order to examinen allele-specific expression in craniofacial structures during embryonic
development. Two control variant constructs were also generated to compare exprimental
results: a) FZD6 rs138557689 which we identified in the African American NSCLP family, for
which the alternate allele led to decreased luciferase expression and b) IRF6 rs642961, for
which the alternate allele led to decreased expression in developing zebrafish in the
publication describing this transgenesis method [36]. This IRF6 variant was also associated
with NSCLP in our family dataset [132, 199] (also see CHAPTER 3). Surprisingly, transgenic
FZD6 rs13855768 animals showed showed increased expression driven by the alterante
allele (mCherry) compared to the ancestral allele (gfp) in the brain, upper lip and lower jaw in
F0 embryos from 2- 5 days post fertilization (dpf). Stable F1s confirmed this expression
pattern, further showing strong regional expression in the midbrain-hindbrain boundary and
the lower oral cavity starting at 48 hpf up to 5 dpf (Figure 31). The ancestral allele drove
expression in some regions of the face in F0 embryos but was not detected in F1s.

Figure 31. F1 FZD6 rs139557689 expression results showed higher alternate allele (mCherry)
expression in the oral cavity (white arrowhead).

IRF6 rs642961, on the other hand, showed a consistent expression pattern in F0 and F1
embryos, with both the ancestral and alterante alleles driving expression in the brain but only
ancestral- gfp expression seen in the lower jaw and oral cavity at both 3 and 5 dpf (p = 0.0009).
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These results are in agreement overall with Bhatia et al findings but the craniofacial structures
where expression was observed differed slightly [199].
The experimental study variants all showed stronger ancestral compared to alternate alleledriven reporter expression in developing craniofacial structures at 3 and 5 dpf. The FZD6
rs75892444 ancestral allele drove reporter expession in the lower jaw cartilages, near the oral
cavity and in the brain while the alteranate construct showed weak expression near the oral
cavity and in the lower jaw cartilages (p < 0.0001, Figure 32). The LRP5 rs4988327 ancestral
allele showed strong expression around the mouth and in the brain while the alternate allele
didn’t show expression in the craniofacial region (p < 0.0001). The LRP6 rs7136380 ancestral
allele drove expression around the oral cavity and in the lower jaw while alterante allele-driven
expression was not detected in these structures but was detected in the brain ( p = 0.002).
Lastly, DKK1 rs7069912 showed strong ancestral allele expression in lower jaw structures
and stong alternate allele-driven expression in the brain, however gfp experssion was
comparatively higher ( p = 0.006) (Figure 32).
Results from stable F1 reporter embryos agreed with F0 results but additionally showed more
specific expression compared to the dispersed expression in the chimeric F0s. FZD6
rs75892544 showed ancestral allele-driven expression in the brain and the corners of the oral
cavity (Figure 33). LRP5 rs4988327 showed very high expression in the brain, olfactory pits
and some expression in the lower oral cavity edges, while the LRP6 rs7136380 ancestral
allele drove more robust and diffuse expression in the brain compared to the alternate allele
which drove weaker expression in a smaller area (Figure 33). Lastly, DKK1 rs7069912
showed expression in the facial muscles including ones in the lower and upper jaw (Figure
33). These dual transgenic reporter zebrafish experiments further nominated 4 variants, one
in each gene, for further study.
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Figure 32. Transgenic reporter expression results at 3 dpf. A. Comparison of ancestral-driven gfp
expression and alternate-driven mCherry expression in the craniofacial regions of F0 transgenic
embryos for each study variant. B. Increased gfp expression was observed for all study variants after
fluorescence was quantified.
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Figure 33. Transgenic reporter expression results at 3 dpf in stable F1 reporter zebrafish.
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5.2.5 Association in NSCLP families
All SNVs were in Hardy-Weinberg equilibrium. Variants in all four genes met the nominal
association threshold of p ≤ 0.05 (Table 14).

After Bonferroni correction, associations

between variants in LRP5 and LPR6 and NSCLP were observed in the NHW white families
while association of variants in FZD6, LPR5 and DKK1 were observed in the Hispanic families
(Table 14). FZD6 rs75892544 was associated with NSCLP in combined Hispanic (p = 4.70E07), multiplex Hispanic (p = 3.00E-05) and simplex Hispanic (p = 0.002) families and no
association was observed in the NHW families. LRP5 rs49883257 and NSCLP association
was observed in both ethnic groups, specifically in all NHW families combined (p =1.49E-04)
multiplex NHW families (p = 8.24E-06), combined Hispanic families (p = 0.004) and simplex
Hispanic families (p = 5.95E-04). LRP6 rs7136380 showed association in combined NHW (p
= 4.4E-05) and multiplex NHW families (p = 5.95E-04), while simplex NHW and simplex
Hispanic families showed nominal association (p = 0.014 and p = 0.04, respectively). Lastly,
DKK1 rs7069912 was associated with NSCLP in the combined Hispanic families (p = 0.002)
and showed suggestive association in the multiplex and simplex Hispanic families (p = 0.03
and p = 0.03, respectively).
Pair-wise gene-gene interactions were also examined in FBAT. In the NHW families,
interactions were found between FZD6 and LRP5 (p = 0.001), LRP5 and LRP6 (p = 2.14E06), LRP5 and DKK1 (p = 1.69E-04) and LRP6 and DKK1 (p = 2.90E-05) (Table 15). In
Hispanics, evidence of interaction was found between FZD6 and the other 3 genes, FZD6 and
LRP5 (p = 2.47E-06), FZD6 and LRP6 (p = 4.85E-04), FZD6 and DKK1 (p = 1.06E-07), as
well as LRP5 and DKK1 (p = 5.30E-05).
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Table 14. FBAT results on FZD6, LRP5, LPR6 and DKK1 variants
All

Hispanic
Families

NHW
Families

GENE

Multiplex

Simplex

SNP
FBAT

FBAT-e

FBAT

FBAT-e

FBAT

FBAT-e

8.24E-06

4.03E-06

FZD6

rs75892544

LRP5

rs4899327

1.49E-04

8.60E-05

LRP6

rs7136380

4.40E-05

1.01E-04

7.05E-04

0.001

0.01

0.02

DKK1

rs7069912

FZD6

rs75892544

4.70E-07

2.80E-06

3.00E-05

1.94E-04

0.002

0.003

LRP5

rs4899327

0.004

0.004

5.95E-04

7.49E-04

LRP6

rs7136380

0.04

0.05

DKK1

rs7069912

0.03

0.03

0.002

0.003

0.03

0.04

Table 15. Gene-gene interaction results for FZD6, LRP5, LPR6 and DKK1 variants.
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5.3 Discussion
Variants in noncoding regions of the genome have been consistently associated with NSCLP
in GWASs and candidate gene studies examining SNVs [35]. One limitation in these studies
is that the biological contributions of the identified/associated variants are difficult to interpret
without follow up functional experiments to provide context and possible explanations for their
etiologic roles. Here we employed an approach where noncoding variants were first prioritized
and tested for functionality and then examined for association with NSCLP, thereby increasing
statistical power by focusing only on variants with strong evidence of functionality. The results
showed that variants with allele-specific protein binding, promoter activity and reporter
expression during vertebrate craniofacial development in FZD6, LRP5, LRP6 and DKK1 were
associated with NSCLP.
NSCLP is a complex disorder that follows a multifactorial model of inheritance, under which
multiple genetic variables are thought to contribute to susceptibility risk [13]. Results showed
support for the association of FZD6, LRP5 and DKK1 in Hispanic families and for LRP5 and
LRP6 in NHW families. The proteins encoded by these four genes, which work at the receptor
level of the Wnt pathway, all influence Wnt signaling [31, 51].

Additionally, significant

statistical interactions were observed between FZD6 - LRP5 and LRP5 - DKK1 in both ethnic
populations. These statistical interactions supported known biological links between FZD
receptors and LPR5/LRP6 co-receptors and between LRP5/6 and their antagonist DKK1 [67].
Differences in the single variant and gene-gene association results between the NHW and
Hispanic families further emphasize the heterogeneity of NSCLP heritability and are in
agreement with other findings of ethnic population-specific genetic liability. These results are
also consistent with the multifactorial model and support the contributions of multiple genes
in susceptibility risk [6, 16, 200].
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Craniofacial morphogenesis is highly regulated and perturbations in gene expression at any
stage of development can alter the resulting facial phenotype. Genetic manipulations to βcatenin mediated Wnt signaling illustrate this point, as overexpression of Dkk1 in Wnt reporter
mice leads to altered Wnt signaling and resulting changes to the morphology of the facial
prominences, thereby increasing the likelihood that an abnormality such as a cleft will occur
(25). To understand how variation in FZD6, LRP5, LRP6 and DKK1 can potentially affect
craniofacial morphology we first characterized β-catenin signaling in developing zebrafish
embryos by examining rostral images of the developing face in a Wnt reporter line.
Intriguingly, β-catenin was highly active in the developing oral cavity starting at 3 dpf and
persisting to 7 dpf.

This pattern of expression is in agreement with findings in

TOPGAL/BATGAL mice where β-catenin signaling is high at the edges of the facial
prominences and observed later in development in the maxilla and lower lip [52, 75].

The

transgenic reporter zebrafish for each study variant also largely drove expression in these
craniofacial regions in both F0 and F1 animals, with the exception of DKK1 rs7069912, which
drove expression in facial muscles.
Genes in the Wnt pathway are known to play crucial roles in craniofacial development and to
contribute to orofacial disorders such as NSCLP [31]. Given the specific expression pattern
of active -catenin signaling around the oral cavity, it was not surprising that abnormal mouth
phenotypes resulted from both knockdown of each gene and from pharmacological
perturbations of this pathway.

Applying ZFACE morphometric analysis allowed the

comparison of phenotypes from each condition and the identification of oral-cavity related
measurements altered by all 4 genes and by activation or inhibition of Wnt signaling. Together
these results suggest that dysregulation of β-catenin signaling in the oral cavity and other
craniofacial structures leads to the formation of abnormal mouth phenotypes and dysmorphic
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craniofacies, signifying possible mechanisms by which differences in gene expression driven
by noncoding variation can contribute to phenotypic changes in orofacial development.
Noncoding variants fine-tune transcription and expression of genes by creating or abolishing
transcription factor binding sites (TFBSs) [37]. The transcription factors by which these
noncoding variants are thought to confer their effects are important and warrant further study.
For example, the FZD6 rs75892544 alternate allele was predicted to create binding sites for
RARα and RARβ, known transcriptional repressors, suggesting lower gene transcription/
expression expected when the alternate allele is present. This was supported by the
transgenic zebrafish reporter results, where the alternate allele drove diminished mCherry
expression. The cell-based results, however, showed increased alternate allele expression in
HeLa and MCF7 cells, while the 293T cells did not show an effect. Retinoic acid is a wellknown teratogen that causes cleft palate in both mice and humans, suggesting that this variant
is a good candidate for examining gene-environment interaction effects, another component
of the multifactorial model of NSCLP [201]. We still do not fully understand how noncoding
variants enact their effects and further studies are needed to elucidate this. Our findings in
the cell-based and zebrafish reporter assays indicate that both in vitro and in vivo assays are
needed to fully evaluate potential effects of noncoding variants.
The strengths of this study come from focused analysis of a set of genes with strong biological
evidence in craniofacial development that act together in the same signaling pathway.
Statistical power was increased by prioritizing and testing noncoding variants in multiple ways,
including in silico, in vitro, and in vivo approaches before examining them in human NSCLP
populations. The use of zebrafish embryos offered the opportunity to interrogate these
variants in high resolution in a developmental time line and allowed the opportunity to perform
supporting expression and perturbation studies to understand the consequences and context
of variant-specific alterations in gene expression.

In summary, this study identified 4
97

functional noncoding variants in Wnt pathway genes that contribute to NSCLP etiology. These
results strengthen the evidence for an etiologic role of FZD6 and LRP6 and provide the first
evidence for LRP5 and DKK1 in NSCLP. They also begin to fill the gap in our knowledge
about the genetic underpinnings of this common birth defect. Our novel approach can be
used in future studies to begin the construction of a map of noncoding genetic contributions
to NSCLP and may ultimately be translated for use in determining individual and family risk
for NSCLP.

98

CHAPTER 6: Summary and Future Directions
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Nonsyndromic cleft lip and palate is the most common craniofacial birth defect occurring in 1
in 700 live births, affecting more than 4000 individuals in the US, and approximately 130,000
individuals worldwide each year [2, 202]. Although surgical therapies have improved facial
outcomes, the associated long-term abnormalities impose significant psychosocial and
financial burdens that negatively impact quality of life [146]. Despite numerous decades of
research, only 20% of the genetic contributions have been identified, explaining only a small
part of NSCLP’s heritability and leaving a large gap in knowledge.
The familial aggregation of orofacial clefts has been recognized since the 1700s, and Fogh
Anderson first documented the birth prevalence, male/female skewing, and segregation within
a Danish family cohort in 1942 [24, 203]. Studies using twin pairs have estimated a high
heritability and NSCLP is classified as a complex disorder following multifactorial inheritance,
where multiple genetic and environmental factors that each have a small effect, act together
in an additive manner [16]. Multifactorial model specifications include: 1) affected children are
most often born to unaffected parents, 2) the risk of recurrence increases with the number of
affected individuals in the family, by severity of the condition, and by gender with the least
often affected sex (in this case females) having a higher liability, and 3) the risk declines by
degree of relationship [6].
Efforts to identify the underlying genetic components have utilized both simplex and multiplex
families and case-control populations, yielding evidence for the involvement of over 40 genes
[24]. Parallel studies in animal models with sporadic clefting, teratogenic causes of cleft
phenotypes and genetic mutations that recapitulate syndromic presentations of orofacial clefts
have yielded support for the involvement of even more genes, environmental factors and
signaling pathways [4].
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More recently, with the feasibility of sequencing the entire genome of an individual, the focus
of human studies is shifting towards in depth genetic interrogation of affected individuals and
their families by whole genome sequencing [204, 205]. This will aid in characterizing variation
in noncoding regions, which is a new direction and may uncover unknown genetic contributors
underlying NSCLP.
The current work examined gene regulatory pathways that are known to be important in
craniofacial development. The first pathway examined was a Pbx-driven regulatory network
that alters Wnt ligand gene expression and controls facial morphogenesis. When this network
is disrupted, it leads to completely penetrant bilateral cleft lip in mice [59]. We followed up on
these exciting results by examining the components of this proposed pathway, both
individually and together, in human NSCLP in Chapter 3. Our results with two independent
datasets found support for the contribution of variation in PBX2 in NSCLP families and PBX1
in case-control comparisons. We also observed significant gene-gene interactions between
PBX2-IRF6, PBX1-WNT9B-IRF6, and TP63-IRF6, further supporting the combinatorial effects
of genetic components of this regulatory pathway and confirming for the first time the
contributions of this pathway to NSCLP risk.
Chapter 4 presented continuing work in our efforts to understand how CRISPLD2, an NSCLP
gene discovered in our lab and confirmed by studies in different populations, contributes to
craniofacial morphogenesis and leads to a cleft when disrupted. We focused on a novel gene,
fos, which was shown to be differentially expressed upon crispld2 knockdown in zebrafish,
and confirmed to play a role in our NSCLP families [33, 151-156, 206].

Although well

characterized as an oncogene and for its regulatory role in bone biology, FOS has not been
studied in the context of orofacial clefting. Our work utilized zebrafish as a powerful model to
show that reduction or absence of fos results in a wide array of craniofacial abnormalities,
including an abnormal mouth and face shape, defects in skeletal components of the
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neurocranium and viscerocranium and tooth anomalies. These novel findings hold promise
for further interrogations of this gene in human NSCLP and for further exploration of the
molecular mechanisms conferred by its dysregulation in the context of CRISPLD2.
Finally, in Chapter 5, we examined noncoding variation in 4 genes that control WNT signaling
at the receptor level that are strongly implicated in regulating craniofacial development and
contributing to NSCLP. We used a novel top-down approach that prioritized and tested
noncoding variants in these genes and shortlisted variants that affect gene expression during
orofacial development in an allele-specific way. After testing these functional variants in a
large dataset of NSCLP families, we observed individual and combinatorial contributions to
NSCLP, paving the way for future studies of these genes and the identification of genetic
signatures that increase NSCLP risk in individuals and families.
Altogether, results from this work enhance our knowledge of regulatory gene pathways in
NSCLP and further the understanding of craniofacial genetics. They present new candidate
genes for replication studies in different ethnic and geographic populations. These results
also have the potential to be translated in the clinical setting for the purposes of providing
improved genetic counseling and assessing individual risk for NSCLP.
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